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ABSTRACT 
Localising the gene for a previously undescribed autosomal recessive 
form of CMT involved the use of a relatively new approach to rapid 
genome screening based on the identification of segments which are 
inherited identical by descent (IBD) from common founding ancestors. 
It is most feasible for populations which have been founded relatively 
recently (say less than 25 generations) and which have remained 
relatively isolated either geographically or culturally. The method is not 
suitable for highly inbred populations, that is with first and second 
cousin matings, as many segments will be inherited by chance. It 
appears to be a suitable screening option for a rare disease trait so 
that the possibility of allelic heterogeneity is reduced. It is also an 
option for those pedigrees where a significant result cannot be 
obtained through traditional linkage analysis, that is, where a large 
nuclear family with many affected individuals is not available. 
Highly informative polymorphic short tandem repeat markers were run 
on the DNA from an initial selection of ten individuals whose inter­
relatedness could be established. In the later stages of the study, 
DNA from forty-seven members of this randomly inbred Bulgarian 
Gypsy kindred was used for verification of the IBD finding by led score 
analysis. 
i 
In the study population where the chosen members are separated from a 
common ancestor by an average 9.4 meioses, the approximate probability 
of finding one random segment (not containii,g the gene) inherited 
identical by descent (IBD) from this common ancestor was calculated at 
9.47 in 1,000 (over 94 markers at an average distance of 12.6 cM). The 
overall probability of finding an IBD segment (not containing the gene) in 
three or more chromosomes decreases to 1.7 in 1 million. This study 
initially identified a 20 cM region on Sq which was shared by three out of 
six non-sibling chromosomes. This region was extended by saturating 
with markers at closer intervals and subsequently a 3 cM segment was 
found to be common among four of six non-sibling chromosomes. Finally, 
lod score analysis on the forty-seven members of the kindred supported 
placement of the candidate gene in this 3 cM segment with a maximum 
led scores at zero recombination for both marker loci D8S558 and 
D8S529 being 3.38 and 2.73 respectively. These two markers are 
mapped at 1 cM apart. 
ii 
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CHAPTER 1. INTRODUCTION 
1.1 Overview 
Hereditary Mot.or and Sensory Neuropathies (HMSN) are disorders 
involving the peripheral nervous system. With an estimated overall 
frequency of 1:2500, Charcot-Marie-Tooth (CMT) disease represents 
the most common HMSN (Lupski et al., 1991). The common clinical 
symptoms of Charcot-Marie·-Tooth disease include weakness and 
atrophy in the distal muscles of the limbs, skeletal deformities, loss of 
deep tendon refiexes and a variable degree of sensory loss. However, 
differences exist between patients with regard to nerve conduction 
velocity, neuropathological findings and mode of inheritance. With 
four different genes (located on chromosomes 1, 8, 17 and X) 
implicated in the development of CMT, the disease is one of the best 
known examples of locus heterogeneity in genetic disorders in humans 
(Ben Othmane et al., 1993; Lupski et al., 1991; Gal et al., 1985). 
Evidence of allelic heterogeneity, that is, different mutations in the 
same gene, has also been documented (Hayasaka et al., 1993b, 
1993c; Roa et al., 1993a, 1993b). In a number of families, linkage to 
any of the known CMT genes has been excluded which suggests that 
additional gene loci involved in the development of the CMT phenotype 
remain to be identified. This is particularly relevant to the autosomal 
recessive forms of the disease, where only one rare CMT gene has 
been localised to date. 
I 
In most autosomal dominant fonns of CMT, neuropathological studies 
have demonstrated the involvement of myelin, the lipid and protein 
Insulating membrane of peripheral nerves (Dyck el a/. 1993; Lupski et
al. 1991). The loss of myelinated fibres, resulting from either faulty 
production or an increased breakdown of myelin, leads to the reduction 
in motor nerve conduction velocities (MCV) typical of these fonns of 
the disease. Before the identific�tion of the genes causing this type of 
CMT, it was not clear whether dysmyelination was a primary 
phenomenon in the pathogenesis of the disease or if it developed as a 
consequence of a primary axonopathy. The issue was resolved in the 
case of the demyelinating autosomal dominant forms of CMT, where 
mutations in genes encoding major myelin proteins were identified (for 
example, CMT18 : myelin protein zero; CMT1A : peripheral myelin 
protein 22). However, the question is s till open in the remaining fonms 
of CMT where as yet no genetic lesion has been found. Given the 
limited knowledge that we have on the interaction between the nerve 
axon and the myelin-fonning Schwann cells, the identification of 
additional genes involved in different forms of CMT will not only 
elucidate the pathogenetic mechanisms of those specific disorders but 
will also contribute to our understanding of the functioning of the 
peripheral nervous system. 
2 
1.2 The cllnlc:al presentation of Charcot-Marla-Tooth disease 
The Charcot-Marie-Tooth neuropathies were named after the clinicians 
who, in 1886, first described patients with the typical clinical symptoms 
of the disease (Lupski el a/., 1991). The invariable clinical features of 
CMT include progressive weakness and atrophy of the distal muscles 
in the leg, foot deformity, reduced deep tendon reflexes and weakness 
of intrinsic hand muscles (Roa el a/., 1993b; Lupski el a/., 1991; 
Chance & Fischbeck, 1994). Differences in the clinical presentation of 
the disease, which serve as the basis of the numerous clinical 
classifications, relate to the age of onset and rate of progression of the 
above-mentioned symptoms, a variable degree of sensory loss, 
changes in nerve conduction velocity and the involvement of myelin, as 
documented by neuropathological investigations. 
1.3 Clinical classification of CMT 
Although the classification of HMSN has varied, and not all authors 
have agreed on divisions between �/pes, Table 1 summarises the 
widely used ,subdivisions which were proposed by Dyck (1975). The 
variable decrease in nerve conduction velocity appears as the most 
important classification criterion from a pathophysiological point of 
view. Slow cond�ction of impulses along the peripheral nerves, as 
3 
CLASSIFICATION 
HMSN Type UCMT1 
HMSN Type IUCMT 2 
HMSN Type Ill 
/OeJerine-Sottas 
HMSNTypelV 
Table 1 Classmcallon by cUnical criteria 
SYMPTOMS 
Weakness & wasting of lower limb 
muscles/f oat deformity/hand 
derormJty/sensory loss/ataxia 
Same as CMT1 but less involvement of 
Intrinsic hand muscles 
ClubrooUdistal weakness & atrophy 
in legs & anns/areflexia /sensory 
toss in all limbs 
Cerebellar ataxia/atypical pigmentary 
relinopathy/deaf ness/foot def onnily 
PATHOLOGY/EMG 
Symmetrically decreased MCV 
(< 38 mtrs/sec)f segmental 
demyelinalion & Schwann cell 
prolif eralion ("onion bulbs") 
Ax.anal neuropathy/normai to 
slightly reduced MCV 
Hypomyelinalion/onion bulbs• 
No myelin• 
Neuronalfnormal to slighlly 
decreased Mcv• 
• These variations in pathology
subsequently used for f urlher
sub-division of this disease.
Increased phytanic acid 
in body fluids 
ONSET OTHER REFERENCES 
1st two decades ·Bird & Kraft (1978) 
Harding & Thomas (1980) 
Bird et al. (1983) 
Mostly 2nd decade Thomas el al. (1974) 
CongenilaVearly 
childhood 
Dyck & Lambert (1974) 
1st lwo decades Baraitser (1990) et1es 
Rersum (1945) 
documented by electromyography {EMG), correlates with the degree of 
demyelination found using light and/or electron microscopy. Nonmal 
conduction velocities are found in those forms of the disease where 
axonal loss, rather than dysmyelination, is the characteristic 
neuropathological feature. 
Peripheral neuropathies, and CMT in particular, have been found to 
occur in association with additional neurological symptoms which are 
not directly related to the peripheral nervous system (Baraitser, 1990). 
These associations include deafness {Cornell et a/., 1984), neL1ral 
deafness and optic atrophy (Iwashita et al., 1970), chronic 
inflammatory demyelinating neuropathy {Gabrsels-Festen & Hageman, 
1986 cited by Baraitser, 1990), spastic paraplegia {Dyck & Lambert, 
1968a, 1968b), optic atrophy {Milhorat, 1943 cited by Baraitser, 1990), 
retinitis pigmentosa and ataxia {Tuck & McLeod, 1983) and congenital 
nephritis (Hanson et al., 1970). In a review of 87 Norwegian families 
with peripheral nauropathies Skre (1974) noted the high incidence of 
non-specific neurological abnormalities in first degree relatives of CMT 
patients, and suggested that in the case of autosomal dominant CMT 
the association may be due to negative selection, in contrast to 
recessive CMT genes which may exert a pleiotropic effect in 
heterozygous carriers. 
s 
Further subdivision of the above types is summarised in Table 2 
according to mode of inheritance. 
Table 2 Classification according to mode or inheritance 
Classification Sub-classification Distinguishing features 
of sub-divisions 
Autosomal dominant 
HMSN Type I CMT1A 
CMT1B 
HMSN Type II CMT2 
Autosomal recessive 
HMSNType I 
HMSN Type Ill 
HMSN Type IV 
X-linked
HMSN Type I 
CMT4A 
CMT4B 
CMT4C 
Dej e rine-Sottas 
Type A1 
Dejeri ne-Sotta s 
TypeA2 
De jerine-Sottas 
TypeB 
Refsum's disease 
X-linked CMT
Intermediate MCV /fewer 
onion bulbs 1
very low MCV/more 
onion bulbs 
(Bird et al., 1983) 
Slow MCV/hypomyelination 
Myelin outfolding 1 /severely 
decreased MCV 
Axonal loss/normal MCV 
(Ben Othmane et al., 1993a) 
Hypomyelination/Onion bulbs 
No myelin 
Axonal loss/normal to 
slightly decreased MCV 
(Baraitser, 1990) 
Slow MCV/onion bulbs 
1 appearance resumng from demyellnaUon and attempted remyellnation 
6 
The pattern of inheritance shows correlation with age at onset and the 
rate of progression of the d isease. The most common forms (CMT1A, 
; B), inherited in an autosomal dominant fashion, are less severe than 
the recessive (CMT4) forms (Ben Othmane el a/., 1993a). In these 
dominant forms, the age of on$el of clinical symptoms is usually in the 
first or second decade, however earlier detection of sub-clinical 
changes is possible by electromyography in those types of CMT in 
which MCV is reduced (Roa et a/.,1993b, Chance & Fischbeck, 1994). 
Although all types of CMT reduce the quality of life of sufferers, they do 
not seem to result in early death (Dyck et a/., 1989). 
1.4 The molecular basis of HMSN 
1.4.1 The role ofmyelin in the peripheral nervous system 
(PNS) 
Myelin is the protein and lipid insulating sheath which, in the 
peripheral nervous system, is formed from the cell membranes 
of Schwann cells. The importance of myelin in the function of 
the peripheral nervous system is evident from comparisons 
made between the speed of transmission of nerve impulses in 
unmyelinated and myelinated axons. An unmyelinated axon 
would need to have a diameter approximately 100 times greater 
than a myelinated axon to achieve equivalent conduction 
velocities (Berne & Levy, 1988, p.44). This increase in the 
speed of conduction is due to increased membrane resistance 
7 
in the axon regions covered by the myelin which results in the 
saltatory conduction of action potentials along the nerve axon 
(Berne & Levy, 1988). 
In addition to the role played by myelin as an insulator of the 
nerve axon, the relationships between axons anj Schwann cells 
may be more complex and interdependent. Evidence that they 
produce neurotrophic factors suggests that these; cells do not 
merely provide structural support but may directly influence the 
growth of axons (Meyer et al., 1992 cited by Suter et al., 1993). 
It is also apparent from studies of the Trembler (TIJ mouse that 
Schwann cells affect axonal transport, neurofilament 
phosphorylation and density (reviewed by Suter et al., 1993). 
These findings suggest that forms of CMT in which myelin is not 
affected may still result from mutations in genes expressed in 
the Schwann cell, but be involved in interactions with axons 
rather than the process of myell.nation. 
1.4.2 Myelin genes associated with PNS disorders 
Genes which have already been identified as being involved in 
myelin production are Peripheral Myelin Protein 22 (PMP22) 
Myelin Protein Zero (MPZ or P0) and Peripheral Myelin Protein 2 
(PMP2). Connexin32 (Cx32), although not expressed in 
8 
compacted myelin, is expressed at the gap junctions at the ends 
of the individual Schwann cells (Bergoffen eta/., 1993). 
Peripheral Mye/in Protain-22 (PMP22)/CMT1A!HNPP 
The peripheral myelin protein 22 gene (PMP22) was mapped to 
region 17p11.2-12 (Matsunami et al., 1992), after Lupski and 
colleagues (1991) found that a 1.5 Mb duplication in this region 
was associated with CMT1A, and Vance and co-workers 
localised CMT1A to 17p11.2 (1991). Two point mutations (one 
recessive), also in the same gene, were found to be associated 
with CMT1A (Roa et al. 1993a, b). A deleted region 
corresponding to the duplicated area on 17p11.2-12 was found 
to result in hereditary neuropathy with pressure palsies (HNPP), 
an autosomal dominant disorder with segmental demyelination 
and tomaculous or sausage-like formations along the peripheral 
nerves (Chance et al., 1993). 
Expression of this axon-regulated PMP-22 gene is up-regulated 
during normal development of Schwann cells in the initial stages 
of the formation of the myelin sheath (Spreyer et al., 1991). It 
has been suggested that the mechanism of dominance in 
CMT1A may be a dosage effect of PMP-22, due to the presence 
of an extra copy of the gene in the duplicated region 
(Matsunami et al., 1992). Conversely, it has been proposed that
9 
under-expression of the PMP-22 gene is the mechanism 
responsible for the HNPP phenotype (Chance el al., 1993). 
Valentijn and colleagues (1995) identified a de novo mutation In 
the PMP22 gene of a patient wiih Dejerine-Sottas disease. The 
patient had an extra exon 1 fragment which was not present In 
the unaffected parents. 
Myelin Protein Zero (MPZIP,JICMT1 B 
Myelin protein zero (MPZ) is the major structural protein of 
peripheral nervous system myelin, accounting for more than 
50% of the sheath protein (Greenfield et al. 1973). Since the 
extra-cellular domain of MPZ has an immunoglobulin-like 
structure (Lemke, 1988) and is similar to an adhesive 
glycoprotein, It. has been proposed that it plays a major role in 
the compaction of myelin (Hayasaka et al., 1993b). 
In 1932 Bird and associates demonstrated linkage of an 
autosomal dominant form of CMT to the Duffy blood group on 
chromosome 1q. A decade later the MPZ gene was localised to 
the region 1q21-q23 (Pham-Dinh et al., 1993). This autosomal 
dominant form of CMT was classified as CMT1 B by Bird el al. 
(1983). In 1991 Lebo and colleagues more precisely mapped 
the CMT1 B gene to the same region. Several point mutations in 
10 
the MPZ gene have since been identified as being responsible 
for CMT1 B (Hayasaka et al., 1993b, Latour et al., 1995). 
Peripheral myelin prDtein-2 (PMP2)/CMT 4A 
Peripheral myelin protein 2 (PMP2) is a small, lipid-binding basic 
protein. The PMP2 gene was mapped to chromosome 8q21.3-
22.1 and its cDNA characterised by Hayasaka and colleagues 
(1993a). 
Interestingly, the first autosomal recessive CMT gene (CMT4A) 
was linked to approximately the same chromosomal region, 
8q13-21.1. The linkage study of CMT4A was conducted on four 
inbred Tunisian families with a total of 13 affected individuals 
(Ben Othmane et al., 1993a). In a subsequent study Othmane 
and colleagues (1995) demonstrated the lack of mutations in the 
PMP2 gene in their CMT 4A patients, providing evidence that 
PMP2 is not the gene involved in this recessive form of Charcot­
Marie-Tooth disease. 
It thus remains to be detenrnined whether a molecular.defect in 
PMP2 is respons'�le for another form of CMT. However, 
together these findings suggest that a cluster of peripheral 
nervous system genes may be located on the long arm of 
chromosome 8. 
II 
Connexin-32/CMTX 
Connexin-32 is expressed in myelinated peripheral nerve at the 
Nodes of Ranvier, rather than In the compacted myelin sheaths. 
The Cx32 gene is located on Xq13-21 and an X-linked dominant 
form of CMT (CMTX) has been mapped to the same region (Gal 
et al., 1985). A number of different point mutations in the Cx32 
gene are now known to cause CMTX (Bergoffen et al., 1993). 
CMTX is a demyelinating neuropathy characterised by 
degeneration of the spinal nerve roots, distal muscle atrophy 
earlier age of onset and increased severity in males. Both 
dominant and recessive forms have been observed. This 
variability of expression is possibly the result of allelic 
heterogeneity (Witkowski and Prokop, 1976 cited by Gal et al., 
1985). 
1.4.3 Other chromosomal regions linked to CMT 
CMT2 
CMT Type 2 is an autosomal dominant axonal neuropathy which 
does not show a dysmyelination patholoJy. CMT2 has been 
localised to the chromosomal region 1 p35-36 (Ben Othmane et 
a/., 1993a) but as yet a gene has not been identified. Locus 
heterogeneity in CMT2 is suggested by the fact that 
12 
approximately 50% of families with this clinical form of the 
disease fail to show linkage to the 1p35-36 region. 
The underlying genetic defect has been identified in a small 
proportion of the CMT types. The known genes responsible for 
the development of CMT encode major myelin proteins and the 
mutations have a dominant effect, as often is the case with 
structural proteins. Although one form of autosomal recessive 
CMT, namely CMT4A, has been mapped, the gene has not 
ber . . cloned and the general molecular mechanisms of 
recessive peripheral neuropathies remain unknown. Since loss 
of function is the general mechanism proposed for autosomal 
recessive disorders, some of these forms of CMT could be 
expected to result from mutations in enzymes involved in the 
complex process of myelin formation and maintenance or in the 
production of signalling molecules involved in Schwann cell -
axon interactions. The identification of such genes lays 
extremely important ground work in the study of normal function 
and pathological changes in the peripheral nervous system. 
1.5 Kindred studied 
A large inter-related group of Gypsy families from the North-West of 
Bulgaria has provided an opportunity to contribute to this important 
area of research. This project is part of a major study conducted in 
13 
collaboration with the Bulgarian Neurosciences and Brain Research 
Foundation. the Department of Neurology and the Laboratory of 
Molecular Pathology at the Medical School in Sofia. 
1.5.1 Demographic background of the Gypsy community 
The group of Gypsies who for.n the study populaticn is know� to have 
migrated from Slip, a small town in the present day Republic of 
Macedonia, in 1886. The community which today numbers about 2000 
was founded by a small group of about 50-100 settlers. Although not 
geographically isolated, the group is endogamous and marriage either 
with non-Gypsy Bulgarians or with Gypsies from other groups is very 
rare. These Gypsies have a sedentary lifestyle. Their history and 
religion prior to settling in the region are not known. 
1.5.2. Clinical presentation of CMT in the Gypsy patients 
Information on the clinical phenotype has been collected in several 
different ways: 
a) neurological screening of numerous individuals, including all
affected persons, performed during field trips; 
b) out-patient examinations of six affected individuals independently
perion11e<l by two neurologists; 
c) detailed assessment during hospitalisation of four patients;
d) retrieval of hospital records from previous admissions of several
additional patients. 
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In the majority of cases the disease became manifest during the first 
decade. The initial symptoms included unsteady gait, weakness in the 
feet and hands, and numbness. Muscular atrophy first develops in the 
distal parts of the limbs and gradually progresses to ir,volve proximal 
muscle groups, leading to severe motor impairment within ten years. 
Neurological examination reveals uniform findings in all affected 
individuals: muscle atrophy, diminished or absent deep tendon 
reflexes, decreased muscle tone and muscle strength, sensory loss, in 
particular of the sense of vibration and joint position, and trophic 
changes in the distal limbs. Hearing loss, especially for high 
frequencies, becomes manifest by the end of the second decade and 
progresses to profound deafness in the fourth decade. 
Electromyography reveals a profound decrease in motor nerve 
conduction velocities from an early age, with complete denervation in 
older patients. Sensory action potentials are unobtainable. The 
conduction velocities along the facial and the glosso-pharyngeal 
nerves are diminished. 
The neuropathological examination of a sural nerve biopsy, obtained 
from a 35 year old patient and performed by Prof. P.K. Thomas at the 
Royal Free Hospital in London, revealed a severe lack of myelinated 
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fibres with unmyelinated fibres relatively well-preserved. No evidence 
of hypertrophic changes of the "onion bulb" type was obtained. 
Electron microscopy demonstrated inclusion bodies of the type 
reported in Refsum's disease, which in this case were described as 
non-specific. The conclusion of the neurological report was that the 
disorder is a severe chronic axonopathy. 
The clinical findings in the Gypsy CMT patients reveal interesting 
features which distinguish the disease from previously described forms 
of CMT. These include: 
a} a marked decrease in nerve conduction velocities which, however, 
is not combined with the typical r.europathological findings of a 
demyelinating neuropathy; 
b} a hearing loss which is slowly progressive and which has been 
shown to be sensorlneural; 
c} the abnormal EMG findings in the facial and other nerves which 
suggest a more generalised cranial nerve involvement. 
1. 5. 3. Genetic analysis
1.5.3.1. Pattern of inheritance 
The overall kindred structure is shown in Appendix B. Although 
affected individuals appear in the pedigree in all generations, 
close Inspection suggests an autosomal recessive mode of 
inheritance. Detailed neurological examinations of a number of 
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the parents of affected individuals, including three couples, has 
revealed only occasional minor abnormalities (such as 
insignificantly diminished tendon refiexes). Nerve conduction 
velocities assessed by EMG in six parental couples were 
normal, with the exception of one mother who had a nearly 50% 
decrease in MCV. These findings are consistent with an 
autosomal recessive transmission of the peripheral neuropathy. 
1.5.3.2. Pedigree analysis 
The genealogical information has been collected during three 
field trips and verified through cross-checking of the information 
obtained from several independent sources. The kindred has a 
complex structure (Appendix 8), with multiple connections 
between affected branches. The overall level of inbreeding 
appears to be low, with no consanguineous marriages at a level 
closer than third cousins. The high frequency of a gene for a 
rare recessive disorder therefore seems to be due to founder 
effect and endogamy rather than to immediate preferential 
inbreeding. The genealogical information obtained sugge�ts the 
presence of affected individuals at least six generations ago 
approximately at the time of settling of the group, which 
indicates that there must have been more than one carrier 
among the founders of the community. 
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1.5.3.3. Molecular genetic studies 
Linkage analysis using markers located close to known CMT 
loci has been performed in the affected Gypsy CMT families. 
The results have demonstrated lac� of linkage to the CMT1A. 
CMT1 B, CMT2 and CMT 4A loci. Linkage to Cx32 has not been 
investigated since there is no evidence of X-linked inheritance of 
the disease. 
In conclusion, the neurological findings, as well as the exclusion 
of linkage In any of the known CMT genes, suggest that the 
disease segregating in this Gypsy community is a novel type of 
CMT whose clinical and genetic characteristics can be summed 
up as follows: 
• 
• 
• 
• 
• 
• 
onset in the first decade initially involving the distal 
muscles of the legs and gradually progressing proximally, 
later involving the hands; 
markedly decreased nerve conduction velocities; 
neuropathological findings suggestive of chronic 
axonopathy; 
cranial nerve involvement, most pronounced in the VII 
cranial nerve; 
autosomal recessive inheritance; 
high gene frequency in an endogamous community with 
presumed founder effect. 
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Given the generalised nature of the defect in this rare form of 
CMT, identification of the gene mutation causing the disease 
can be expected to make an important contribution to our 
understanding of the peripheral nervous system and· its 
disorders. 
1.6 Approaches to mapping autosomal recessive disorders 
Approaches to mapping disease genes vary depending on a number of 
variables, such as the pattern of inheritance, the gene frequency, the 
number of families and affected individuals available for analysis, and 
the characteristics of the population and families where the disease 
trait occurs. 
These parameters affect the choice of the mathematical approach to 
estimating the probability of linkage to a specific chromosomal region. ' 
However, a common feature of all approaches to mapping is the use of 
polymorphic markers ,:,f known chromosomal location and whose co­
segregation with the disease phenotype can be traced. The 
polymorphic markers which currently are most widely used are a class 
of DNA repeats known as microsatellites. Microsatellite markers are 
simple di-, tri- or tetranucleotide units whose polymorphism is related to 
the variable number of repeats. The availability of such markers is 
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exponentially increasing with several international consortia working on 
the identification and mapping of microsatellites (Weber & May 1989; 
Botstein et al., 1980; Gyapay et al., 1994; Weissenbach et al., 1992; 
Co-operative Human Linkage Centre (CHLC): NIH/CEPH Collaborative 
Mapping Group). A map of the human genome indicating the 
chromosomal location of a large number of microsatellite repeats is 
already available and is subject to regular updating. The 
microsatellites on this map can be used as reference points and the 
position of any disease gene can be established relative to markers of 
known location. Apart from the large number of alleles and hence the 
high informativity of this class of polymorphic markers, an additional 
advantage over classical markers such as the RFLPs is the possibility 
of utilising PCR technology in the molecular analyses. The unique 
DNA sequences which precede and follow a microsatellite repeat can 
be used to design primers for the polymerase chain reaction. Since 
differences between the alleles are related to the number of repeats, 
the analysis involves size separation of the PCR products. 
A number of strategies have been designed to estimate the probability 
that a disease gene is located close to a specific polymorphic marker 
or set of markers: 
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1.6.1 Linkage analysis 
The usual approach to mapping disease genes where no prior 
knowledge of gene product is available is conventional linkage 
analysis or positional cloning. The basis of this approach is to 
t race the segregation of the disease gene and the alleles of a 
polymorphic marker and, by assessin g co-segregation, establish 
their distance from each other. If the disease gene and the 
marker in vestigated are located on different chromosomes they 
wil  be inherited independently of each other. If they are located 
on the s ame chromosome, the probability of co-inheritance 
increases as t he distance between the two decreases, since the 
chances of a recombination decline within a small segment of a 
chromosome. The statistical power of this approach depends 
on the availability of large pedigrees for analysis. The use of 
multiple small affected pedigrees is an alternative, however, this 
is highly dependent on the assumption of locus homogeneity. 
The results of linkage analysis are presented as LOO scores 
(logarithm of the odds) in favour of linkage calculated at different 
recombination frequencies represented by e. By convention, 
evidence of linkage is accepted at a l od score of 3 which means 
odds 1000:1 in favour of linkage (Morton, 1955). 
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1.6.1.1 Homozygosity mapping 
Rare autosomal recessive disorders in closely inbred pedigrees 
usually occur as the result of the inheritance of the same 
disease gene from a common ancestor. If the common ancestor 
is a small number of generations away, the whole chromosomal 
region containing the disease gene will be transmitted in its 
original form, i.e. the affected individuals can be expected to be 
homozygous for both the disease gene and the alleles of the 
polymorphic markers located in close proximity. This has 
formed the basis of an approach known as homozygosity 
mapping (Lander & Botstein, 1987). Unlike conventional 
linkage analysis, homozygosity mapping allows the localisation 
of a disease gene through the analysis of a small number of 
F-Jfected individuals 1 provided that two conditions are fulfilred, 
namely a high inbreeding coefficient in the family and a low 
frequency of the disease gene. 
1.6.1.2 Segment sharing based on linkage disequilibrium 
A recent strategy used in mapping recessive genes in isolated 
populations is segment sharing (Houwen et al., 1994). This 
method involves the identification of shared chromosomal . 
segments (haplotypes) which are inherited in a manner that is 
described as identical by descent (IBD) (Houwen et al .• 1994). 
Mapping by identifying shared segments, or extended regions of 
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chromosomes which have been inherited from a common 
founding ancestor, requires three pre-conditions: 
1) the disease should be rare,
2) the study population is isolated and
3) the population is derived from a small number of founders.
Unlike homozygosity mapping, segment sharing does not 
require a high level of inbreeding and so it is believed to be 
most appropriate in cases when the affected individuals are 
related via a common ancestor six to ten generations ago. 
Calculations are made on the probability of several distantly 
related individuals having inherited the same chromosomal 
segment from a common ancestor or a set of ancestors, and a 
set of formulae have been developed which calculate the 
probability of a false positive finding, i.e. a segment inherited 
IBD which however does not contain the disease gene (Houwen 
et al., 1994). A major benefit of this mapping technique is that 
only a very small number of individuals need to be analysed In 
order to achieve a statistically meaningful result. 
1.7 Aim of the research 
The aim of this project was the localisation of the gene for a novel form 
of Charcot-Marie-Tooth disease (CMl) in an isolated human 
population. 
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CHAPTER 2, METHODS 
2.1 Kindred studied 
2.1.1 Pedigree 
Pedigree information has been collected by the Laboratory of 
Molecular Pathology, Sofia, Bulgaria during three field trips. 
The information obtained from at least two independent sources 
has been cross-referenced to verify the connections between 
separate branches of the pedigree. The structure of the final 
diagram has been confirmed by several key informants. The full 
diagram of the kindred is shown in Appendix B. For the 
purposes of this study, a simplified version of the pedigree 
(Appendix C), including most of the affected branches, has been 
compiled by Dr. Luba Kalaydjieva. 
The inbreeding coefficient for this pedigree was calculated using 
the computer program Kinship (Boyce, 1983). The gene 
frequency for the Bulgarian Gypsy population was calculated 
using Hardy-Weinberg: p2 + 2pq + q2 = 1 {where p
represents the normal gene frequency and q the disease gene 
frequency). 
2.2 Laboratory procedures 
In order to obtain the marker allele segregation data for analysis, the 
procedures followed were: 
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PCR to amplify the different specific regions of DNA 
PAGE to separate the amplified DNA fragments by size 
• Visualisation of the separated fragments
Assignment of allele numbers to the fragments
Entry of the alleles on to the pedigrees
Haplotype analysis
DNA had been extracted from peripheral blood lymphocytes by the 
Laboratory of Molecular Pathology, Medical School, Sofia, Bulgaria. 
The concentration of each sample had been determined. The range of 
DNA concentration across the samples varied from 16 ug to 755 ug.
The list of DNA concentrations per sample are in Appendix D. A stock 
bank of DNA at the original concentrations was maintained at -20°C. A 
working solution was made by diluting with sterile H20 (Baxter) to a 
concentration of 2.Sug/ml. 
2.2.1 DNA amplification via polymerase chain reaction (PCR) 
The method of amplifying specific regions of DNA is the 
polymerase chain reaction (PCR), devised by Mullis & Faloona 
(1987). This method utilises an enzyme to exponentially amplify 
a DNA sequence. The basic requirement is knowledge of part 
of the sequence at the ends of the target DNA region, so that 
Initiation of the extension of the complement to the template 
strand can be accomplished. These sequences, referred to as 
2S 
PCR primers, bind to their complementary base pairs starting at 
the 5' ends of the single target strands. The target DNA defined 
by the primers is enzymatically amplified through a series of 
denaturing, annealing and extension steps. These three steps 
are performed at different temperatures and form one PCR 
cycle. The standard PCR protocol usually includes thirty cyclPs. 
The number of copies of the target sequence increases 
exponentially, which allows easy identification and visualisation 
using any of a number of techniques e.g. autoradiography, 
fluorescence. 
Polymorphic DNA markers (average heterozygosity of 79%) 
from the Genethon map were used to probe family DNA for 
evidence of linkage to the disease gene. The PCR primers for 
these markers were synthesised by Research Genetics 
Laboratories, California. 
Protocols for the amplification of the specific DNA marker 
sequences using PCR are detailed in Appendix F. 
Protocols for using the capillary system of PCR are In 
Laboratory protocols in Appendix F. 
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2.2.2 Methods of detection 
To visualise the PCR products after electrophoretic separation, 
the following three labelling methods were used: 
radioactive nucleotide incorporation 
fluorescent deoxyuridine triphosphate ([f]dUTP) 
incorporation 
fluorescent end-labelled primers. 
Radioactive nucleotide and [f]dUTP methods use the same 
principles, in that the labelled nucleotides are incorporated 
(along with the other free dNTPs) by complementary base 
pairing into each new strand of DNA as it is synthesised by the 
polymerase. For visualisation in the case of dUTP labelling, one 
of three rhodamine dyes (R110, R6G or Tamra) are added to 
the PCR master mix. The same thenmal cycling conditions are 
used as in the radioactive labelling. The fluorescent end-labelled 
primers differ because the label is not incorporated along the 
strand, ii is only present at the 5' end of each primer. These 
dyes are attached via a linker molecule during synthesis of the 
primers. 
2.2.3 Polyacrylamlde gel electrophoresis (PAGE) 
Under the influence of an electrical current the negatively 
charged DNA moves towards the positive electrode. In the case 
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of PAGE, the gel is set up in a vertical orientation and the 
amplified PCR products are loaded into wells at the top. 
Migration of the products is dependent upon the pore size of the 
gel matrix, the size of the product, and the level of electrical 
current applied. The larger the product fragment, the slower is 
its migration through the gel. The choice of 4%, 6% or 8% (WN) 
polyacrylamide depended on the sizes of DNA fragments to be 
separated. Most allele sizes fell into the range of 100 base pairs 
(bp) to 250 bp, which were suitable for running on 6% (WN) 
gels. Alleles smaller than 100 bp gave better separation on 8% 
(WN) gels, as the pore sizes resulting from the cross-linked 
monomers were smaller. Similarly, 4% gels with larger pore 
sizes were more suited to fragments > 250 bp. 
2.2.4 Visualisation 
Visualisation of the separated fragments was dependent upon 
which of the methods of labelling were used (radioactive or 
fluorescent). 
Radioactive method: The alleles are visualised as dark lines on 
an autoradiograph after the dried gel is exposed overnight at 
room temperature to X-ray film and developed. Details are 
listed in "Post-run procedures radioactive labelling' in Appendix 
E. 
28 
Fluorescent methods: The alleles are au:�matically sized 
relative to an internal size standard (in number of base pairs) by 
the Genescan software, which is used in conjunction with the 
ABI Prism™ 373 DNA Sequencer on which the fluorescent 
products were run. The principles of operation are: 
2.2.4.1 Fluorescent methods (Principles of 
operation of the ABI Prism™ 373 DNA Sequencer) 
A vertical polyacrylamide gel is loaded with the 
fluorescently-labelled PCR products which migrate 
downwards to pass a laser-scanning window. Several 
markers can be run in each lane as differentiation is via 
the size of the alleles and the different colours of the 
fluorescent dyes. The alleles are sized relative to an in­
lane sizing standard (Perkin-Elmer). Sizes are recorded 
in base pairs to an accuracy of 2 decimal points. This has 
the a dditional benefit of standardising sizes between 
· lanes and gels. An argon laser which moves on a track
behind this scanning window excites the fluorescent
particles which emit light. These light wavelengths are
detected by a photomultiplier tube (PMT) and are
converted to an electrical signal which is digitally stored
by a Macintosh computer connected to the sequencer.
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The visualisation of the varying intensities of fluorescence 
is via peaks which are graphically displayed on an 
electrophoretogram. 
The raw data collected during scanning are down-loaded 
during the run to the computer and stored in a collection 
file on a portable hard disk for later processing. The 
processed data are available in tabular form as well as 
the electrophoretogram display. 
2.2.5 Assignment of alleles 
Radioactive method: The lanes were numbered with the 
pedigree numbers on the autoradiograph. The allele numbers 
were then assigned with number one allele designated as the 
uppermost band and the largest sized fragment. 
Fluorescent methods: The sized alleles were re-numbered 
in the same manner as the radioactively labelled alleles, that is 
with the largest fragment numbered one followed by consecutive 
numbers as the sizes reduce. This is not usuall;' necessary but 
was done for consistency in allocating haplotypes. 
The assigned alleles were then entered on to pedigree charts 
using the computer prcgram Cyrillic. The marker data were 
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entered in the same order as the markers appear on the 
chromosome map (Genethon) so that the haplotypes were 
shown. 
2.2.6 Haplotypes 
Marker allele data were entered for each chromosome, with 
marker numbers in consecutive order from the telomeric tip of 
the p arm to the tip of the q arm. Haplotypes were formed by 
first setting phase (where possible) for the key affected 
members 38, 13 and 4 for each set of marker alleles such that 
the paternal allele was on the left. Where phase was unknown, 
e.g. where both parents were heterozygous for the same alleles,
it was indicated on the pedigree. For the sake of consistency, 
haplotypes were then formed with the inherited paternal 
haplotype of each key individual placed in the left position of the 
father's two chromosomes. Similarly, the inherited maternal 
haplotype was positioned on the left of the mother's two 
chromosomes. 
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CHAPl'cR 3. RESULTS 
3.1 Choice of approach 
In order to gain more information on the likely genetic structure of the 
population and to find the most appropriate method of analysis, the 
computer program "Kinship" (Boyce, 1983) was used to calculate 
individual inbreeding coefficients, and the average inbreeding 
coefficient for the population. The inbreeding coefficients for most 
individuals were zero, however the values for patients 2 and 4 were F
= 0.003 (this was expected due to the parents being third cousins). 
The kinship coefficients for pairs of individuals were also calculated. 
These are summarised in Table 3. Appendix G details the output from 
the Kinship program including the common ancestor pathways. 
Table 3 Kinship coefficients 
First individual Second individual Kinship coefficient 
38 13 0.001 
38 4 0.002 
13 4 0.016 
26 4 0.004 
36 26 0.016 
The gene frequency for the Bulgarian Gypsy population (approximately 
two thousand in number with fifteen known affected members) was 
estimated using the Hardy-Weinberg formula (p2 + 2pq + q2) with q2 =
15/2000 (15 affected individuals in total population of 2000) therefore, 
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the disease gene frequency , q = ;/15/2000 = 0.086. This high 
disease gene frequency in the population together with the low 
inbreeding coefficient in the sub-population under inve.stigation makes 
homozygosity mapping an unsuitable choice of strategy for this study. 
As previously stated, homozygosity mapping relies on a low gene 
frequency and a high inbreeding coefficient (Lander & Botstein, 1987). 
Conventional linkage analysis was not feasible as a screening 
approach for the pedigree as a whole due to the extensive number of 
inter-family connections. These relationship loops result in 
impracticably long computer processing times (e.'.,. 24 hours for 1 
marker). However, this method can be used to a minor extent as an 
end stage screening on a small number of markers, with only the main 
inter-family connections included. 
3.2 Analysis strategy 
3.2.1 Overall design of the analysis 
With the above restrictions in mind, it was decided that the rapid 
genome screening approach based on searching for shared 
segments, reported by Houwen and associates (1994) and as 
described in Chapter 1, was appropriate for this population. 
Collaboration with one of the initiators of the method, Lodewijk 
Sandkuijl, was obtained. The collaboration involved the 
selection of the most informative members of the pedigree. 
This selection was made from a simplified version of the original 
pedigree. The highlighted individuals are shown in Appendix C. 
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The analysis followed four stages: 
Preparatory stage : The preparatory stage of the study 
involved the selection of individuals. 
Stage 1: This stage of the analysis involved 
identification of 'mini-haplotypes', i.e. identical segments 
(regions bounded by two adjacent markers) shared by at least 
three of six affected (non-sibling) chromosomes. 
Stage two: These two-marker haplotypes were extended 
internally by running extra markers at closer intervals (- 3 cM 
apart). 
Stage three : The extended pedigree (47 members) was 
run for those markers involved in shared haplotypes which 
remained in three or more non-sibling chromosomes. 
3.2.1.1 Preparatory stage : Selection of individuals 
The individuals were selected according to criteria based 
on their degree of relatedness being present but low (that
is they shared a traceable distant common ancestor). 
The individuals chosen were related through a total of six 
possible pathways, however the five pathways with the 
minimum number of steps were used in the calculation of 
average separation of 9.4 generations or meioses from 
the closest common ancestor. This pre-condition 
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reduced the amount of segment sharing by chance alone 
and this was determined in the following manner: 
Individuals numbered on the pedigree as 38, 13 and 4 
were designated as the key members. These individuals 
are from three nuclear families, the first containing both 
parents and one affected daughter, the second 
containing a mother and two affected siblings, and the 
third containing both parents and two affected siblings. 
Parents 45, 47 1 10, 3 and 1 were included for 
determination of haplotypes and affected siblings; 49 
and 2 were included for comparison of haplotypes (e.g. if 
an affected sib did not share the same region it probably 
would not be linked to the disease ger.e). The 
relatedness pathways are illustrated by five different 
colours as shown on the pedigree in Appendix C and are 
as follows: 
Path 1 :-ed 38 via 47 to 13 via 10 10 steps 
Path 2 green 38 via 45 to 4 via 1 9 steps 
Path 3 blue 38 via 45 to 4 via 3 11 steps 
Path4 yellow 13 via father to 4 via 1 6 steps 
Path 5 pink 4 via 1 to 4 via 3 1 j &1a�& 
The average number of steps (each step represents a 
meiotic event or generation) 47/5 = 9.4. 
3S 
DNA was used from affected siblings to obtain additional 
information on haplotypes. For example, in regions 
where three or more of six chromosomes were identical 
in affected persons but where siblings showed different 
haplotypes in these areas, it was an indicator that it was 
unlikely to contain the disease gene. Conversely, where 
the affected siblings showed the same haplotypes, ii 
indicated that the region may have contained the disease 
gene. DNA from the parents of affected members was 
used where available, in order to determine the parental 
origin of alleles (to set phase) to assist in tracing 
inheritance routes and for the construction of haplotypes. 
3.2.1.2 Prnbability of false positive findings 
Several formulae (Houwen et al., 1995) were used to 
arrive at an overall probability of finding a false positive 
anywhere in the genome i.e. an IBD region which does 
not contain the disease gene. The initial formula 
p1(x) = 0.59(1-0.01x)9
was used to calculate the approximate probability of 
finding a rando:n chromosomal segment between two 
markers x cM apart that was identical to that of an 
ancestral chromosome g generations ago (Houwen et al., 
1995). For example, the probability (p1) of one random 
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11 cM segment (not containing the disease gene) being 
inherited identical by descent (IBD) from an ancestor 9.4 
generations ago is 1 in 2000 (Table 4). A second 
calculation p2 estimated the probability that k of n 
chromosomes transmitted via a common ancestor g 
generations ago would be IBD between two markers x 
cM apart where 
p2 (k, X) = (nCk) . (p1 (x))'. (1 - p1(x))"''. 
Thus the probability of three out of six chromosomes 
sharing an 11 cM IBD segment (not containing the 
disease gene) from 9.4 generations ago was calculated 
at 2.42'9 (Table 4). 
However, as the IBD segment could have come from any
one o• four ancestral chromosomes, the following 
formula was used to evaluate the probability of its 
occurrence in three or more chromosomes: 
p,(k,x) = 4. L p2 (i,x). 
This gave a total probability of an 11 cM segment (not 
contain, q the disease gene) being inherited IBD in three 
to six chromosomes (i.e. the sum of the probabilities fork 
= 3 to k = 6) as 9.69 x 10'9 (Table 4). 
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Table4 PROBABILITY OF FALSE POSITIVE IBD FINDINGS· SEGMENT SHARING METHOD 
Distance Marker p1 p2(n=6;Joo3) p2(n=6;k=4) p2(n=6;k=5) p2(n=6;k=6) Sumofp2 p3 p3 x frequency 
between Frequency fork= 3 .. 6 4*sum p2 for k=3 .. 6 
markers 
xcM 
2 2 .22E~3 3.66E.()8 3.36E-11 1.65E-14 3.37E-18 3.66E.()8 1.46E.()7 2.93E.07 
4 3 1.01E.()3 2.05E-08 1.55E-11 6.25E-15 1.05E-18 2.05E-OB 8.19E-OB 2.46E.07 
6 5 8.27E.()4 1.13E-08 · 7.02E-12 2.32E-15 3.21E-19 1.13E.()8 4.52E.()8 2.26E.07 
7 7 7.48E.o4 8.36E.09 4.70E-12 1.41E-15 1.76E-19 8.37E-09 3.35E-OB 2.34E.07 
8 4 6.76E.()4 6.16E-09 3.13E-12 8.46E-16 9.54E-20 6.17E.()9 2.47E.()8 9.87E.08 
9 8 7.48E.()4 8.36E-09 4.70E-12 1.41E-15 1.76E-19 8.37E.()9 3.35E.()8 2.6BE.()7 
10 7 5.50E.()4 3.32E.()9 1.37E-12 3.01E-16 2.76E·20 3.32E.()9 1.33E.()8 9.29E.08 
11 6 4.95E-04 2.42E-09 8.99E-13 1.7BE-16 1.47E-20 2.42E-09 9,d9E-09 5.81E.OB 
12 7 4.45E.()4 1.76E-09 S.BBE-13 1.05E-16 7.7BE-21 1.76E-09 7.05E-09 4.93E.08 
.., 13 8 4.DOE-04 1.2BE-09 3.83E-13 6.12E-17 4.08E-21 1.28E.()9 5.11E.()9 4.0BE.OB 
"' 14 11 3.59E.()4 9.21E-10 2.4BE-13 3.56E-17 2.13E-21 9.21E-10 3.69E-09 4.05E.08 
15 3 3.21E-04 6,62E·10 1.60E-13 2.05E-17 1.10E-21 6.63E-10 2.65E-09 7.95E.09 
16 4 2.87E-04 4.75E-10 1.02E-13 1.18E-17 5.64E-22 4.75E-10 1.9DE-09 7.59E.09 
17 3 2.57E.()4 3.39E-10 6.52E-14 6.70E-18 2.87E-22 3.39E·10 1.35E-09 4.06E.09 
18 5 2.29E.()4 2.41E-10 4.14E-14 3.79E-18 1.45E-22 2.41E-10 9.62E-10 4.81E.09 
20 2 1.B2E.()4 1.20E-10 1.63E-14 1.19E-1B 3.60E-23 1.20E-10 4.80E-10 9.59E-10 
21 1 1.S1E-04 8.41E-11 1.02E-14 6.58E-19 1.77E-23 8.41E-11 3.3SE-10 3,36E-10 
22 2 1.43E-04 5,87E-11 6.31E-15 3.62E-19 8.63E-24 5.87E-11 235E-10 4.70E-10 
24 1 1.12E..04 2.82E-11 2.38E-15 1.07E-19 1.99E-24 2.82E-11 1.13E-10 1.13E-10 
25 1 9.91E-05 1.94E-11 1.44E-16 5.72E-20 9.45E-25 1.94E-11 7.77E-11 7.77E-11 
26 2 6.73E-05 1.33E-11 8.72E-16 3.05E-20 4.43E-25 1.33E-11 5.32E-11 1.06E-10 
29 1 S.DZE-05 4.14E-12 1.84E-16 4.35E-21 4.29E-26 4.14E-12 1.66E-11 1.66E-11 
30 1 5.1BE.()5 2.78E-12 1.0BE-16 2.24E·21 1.93E-26 2.78E-12 1.11E-11 1.11E-11 
94 9.47E.()3 1.65E.()5 1.1BE-07 4.53E-10 7.22E-13 1.03E.()7 4.12E.()7 1.67E-<16 
Average no. generatio~ (g)= 9.4; k = No. of shared segments; n =Total No. of chromosomes (6) 
TableS PROBABILITY OF FALSE POSITIVE IBD FINDINGS - SEGMENT SHARING METHOD 
Distance Marker p1 p2{n-=B;k=3) p2(n=6;k=4) p2(n=6;k=5) p2(n-6;k=6) Sum ofp2 p3 p3Xfreq""""Y 
between Frequency fork=3 .. 6 4•sum p2 
markers fork=<3 .. 6 
xcM 
1 3 1.35E.03 4.B7E-OB 4.92E-11 2.65E-14 5.97E-18 4.87E-OB 1.95E-07 5.64E-07 
2 4 1.22E-03 3.66E-DB 3.36E-11 1.65E-14 3.37E-18 3.66E-08 1.48E-<17 5.85E-07 
3 5 1.11E-<13 2.74E..OB 2.29E-11 1.02E-14 1.89E-1B 2.74E-OB 1.10E..07 5.48E-07 
4 6 1.01E-<13 2.05E-<IB 1.55E-11 6.25E-15 1.05E-18 2.05E-08 8.19E-<18 4.91E-07 
5 2 9.14E-<14 1.52E...08 1.04E-11 3.B2E-15 5.83E-19 1.52E-08 6.09E..Q8 1.22E-<l7 
6 6 B.27E-<14 1.13E-<IB 7.02E-12 2.32E-15 3.21E-19 1.13E-OB 4.52E-<IB 2.71E-<17 
7 10 7.48E-04 8.36E-09 4.70E-12 1.41E-15 1.76E-19 8.37E-09 3.35E-08 3.35E-07 
8 4 6.76E-<l4 6.16E-<19 3.13E-12 B.46E-16 9.54E-20 6.17E-09 2.47E-<18 9.87E-OB 
9 B 7.48E-04 8.36E-09 4.70E-12 1.41E-15 1.76E-19 a37&oa 3.35E-08 2.68E-<17 
10 6 5.50E-<14 3.32E-<l9 1.37E-12 3.01E-16 2.76E-20 3.32E-09 1.33E.08 7.97E-<18 
11 6 4.95E-04 2.42E-09 8.99E-13 1.78E-16 1.47E-20 2.42E-09 9.69E..{)9 5.81E-08 
.., 
12 7 4.45E-04 1.76E-<19 5.88E-13 1.05E-16 7.7BE-21 1.76E-09 7.05E-<19 4.93E-<IB 
"' 13 8 4.00E-<14 1.2BE.09 3.83E-13 6.12E-17 4.08E-21 1.2BE-09 5.11E.09 4.0BE.OB 
14 11 3.59E-<14 9.21E-10 2.48E-13 3.56E-17 2.13E-21 9.21E-10 3.69E-09 4.05E.OB 
15 4 3.21E-<14 6.62E-10 1.60E-13 2.05E-17 1.10E-21 6.63E-10 2.65E.09 1.06E.08 
16 2 2.87E-<14 4.75E-10 1.02E-13 1.18E-17 5.64E-22 4.75E-10 1.90E.09 3,80E..Q9 
17 3 2.57E..04 3,39E-10 6.52E-14 6.70E-18 2.87E-22 3.39E-10 1.35E-09 4.06E-09 
18 5 2.29E-04 2.41E-10 4.14E-14 3.79E-18 1.45E-22 '2.41E-10 9.62E-10 4.81E-09 
20 1 1.82E-04 1.20E-10 1.63E-14 1.19E-18 3.60E-23 1.20E-10 4.BOE-10 4.80E-10 
21 1 1.61E-<14 6.41E-11 1.02E-14 B.SBE-19 1.ne-2a 8.41E-11 3.36E-10 3.36E-10 
22 2 1.43E-04 5.87E-11 6.31E-15 3.62E-19 8.63E-24 5.87E-11 2.35E-10 4.7DE-10 
25 1 9.91E-05 1.94E-11 1.44E-15 5.72E-20 9.45E-25 1.94E-11 7.77E-11 7.77E-11 
26 2 8.73E-OS 1.33E-11 8.72E-16 3.05E-20 4.43E-25 1.33E-11 5.32E-11 1.06E-10 
29 1 5.92E-05 4.14E-12 1.84E-16 4.35E-21 4.29E-26 4.14E-12 1.66E-11 1.66E-11 
30 1 5.1BE.05 2.7BE-12 1.08E-16 2.24E-21 1.93E-26 2.7BE-12 1.11E-11 1.11E-11 
109 1.27E-<12 1.94E.07 1.55E-10 7.00E-14 1.37E-17 1.94E-07 7.77E.07 3.60E-<18 
Average no. generations {g)= 9.4; k =No. of shared segments; n =Total No. of chromosomes (6) 
Finally, the overall probability of finding a segment which 
is shared 180, but does not contain the gene, having run 
89 markers covering 94 intervals at varying lengths and 
frequencies, was calculated using p3 x marker frequency 
for each interval. Houwen & colleagues noted that this 
formula does not take into account the probability of a 
false 180 finding in one interval not being independent of 
a similar finding in an adjacent interval. However, the 
summary of the p3 values over all the intervals covered 
in Stage 1 of this study resulted in an overall probability 
of a false positive 180 finding being approximately 1 in 
600,000 (1.67 x 1o·')(Table 4). When the extra markers 
for Stage 2 are taken into account (109 intervals in total), 
the probability increases to 1 in 278,000. This is due to 
the increased number of smaller intervals and reduction 
in larger segments (Table 5). That is, there is a greater 
chance of false positive findings with srnaller intervals 
between markers. 
3.2.2 Feasibility of the study 
3.2.2.1 Jnformativity of polymorphic markers 
The polymorphic marker loci information was taken from 
the Genethon microsatellite map catalogue (Gyapay et
a/., 1994) and map distances were sex-averaged. The 
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average distance between the marker loci was 11 cM 
and the average published heterozygosity was 0. 79. 
In order to obtain an estimation of the heterozygosity 
index in this population, and therefore to determine 
whether the markers used were appropriate, ten unlinked 
markers were analysed. These markers were run on 
extended versions of Iha pedigree as follows: three on 
chromosome 1 (D1S233, D1S186, D1S228), three on 
chromosome 8 (not linked to the gene region) (D8S88, 
DBS279, DBS257), three on chromosome 17 (D17S578, 
D17S849, D17S796) and one on chromosome 5 
(D5S819). The number of alleles per marker versus the 
number of alleles published for the CEPH families and 
obtained from the Genome Data Base is listed in Table
6. 
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Table 6 
Locus name 
D18233 
D1S1B6 
D1S22B 
D5SB19 
D8S8B 
D88279 
08$257 
D17S578 
D17SB49 
D17S796 
Number of alleles in a sample of 1 O markers 
run for the extended pedigree 
Actual# 
alleles 
6 
9 
5 
5 
10 
10 
5 
4 
4 
5 
Published# 
alleles 
9 
10 
7 
Not listed 
10 
10 
9 
11 
6 
a 
Allele frequencies were calculated and are shown in Table 
7. Frequencies could not be compared to the published
frequencies as allele numbers were allocated on a relative 
basis for the radioactively labelled markers. 
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Table 7 Allele frequencies for 10 unlinked marker loci 
n = no. of chromosomes/marker 
Allele# 018233 018186 018228 058819 08888 088279 088257 0178578 0178849 0178796 
n= 70 90 66 66 92 90 98 62 62 68 
1 0.04 0.04 0.07 0.27 0.16 0.15 0.04 0.04 0.24 0.14 
2 0.17 0.07 0.04 0.17 0.12 0.15 0.30 0.07 0.60 0.07 
3 0.17 0.07 0.26 0.23 0.02 0.05 0.14 0.58 0.04 0.14 
4 0.35 0.03 0.52 0.17 0.02 0.05 0.47 0.31 0.12 0.24 
5 0.17 0.14 0.11 0.17 0.19 0.02 0.05 0.41 
6 0.10 0.14 0.28 0.02 
7 0.31 0.07 0.32 
8 0.17 0.07 0.02 
9 0.03 0.05 0.05 
10 0.02 0.17 
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As a measure of the degree of polymorphism of this 
sample of ten markers Table 8 shows the heterozygosity 
calculations. This population is very heterozygous with 
four of the markers giving a higher obsmved 
heterozygosity than the published figures, an indication 
that these markers are highly polymorphic for this 
pedigree. 
Table 8 Heterozygosity calculations 
Marker# # Hetero- Total# Observed Published 
zygotes individuals Heterozygosity 
01$233 29 35 0.83 0.84 
01$186 31 45 0.89 0.84 
D1S228 19 33 0.57 0.76 
05$819 30 35 0.86 0.83 
08888 43 49 0.88 0.82 
DBS279 35 45 0.78 , 0.86 
OBS257 33 49 0.67 0.71 
017$578 21 31 0.68 0.63 
D17S849 '18 31 0.58 0.67 
D17S796 21 34 0.62 0.81 
Table 9 shows the calculation of the inbreeding coefficient of the 
pedigree by firstly finding the expected heterozygosity using the 
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formula H = 1 • I: p12 where H is the actual heterozygosity 
obseived and p1 is the allele frequency. Then F = ( H0 • H) / H0
where F is the inbreeding coefficient and H0 is the expected
heterozygosity for a randomly mating population.
Table 9 Calculation of coefficient of inbreeding for 1 O 
unlinked marker loci 
Marker# I:pi2 Ho H F 
(Expected) (Actual) 
D1S233 0.22 0.78 0.83 0.00 
D1S186 0.18 0.82 0.89 0.12 
D1S228 0.35 0.65 0.57 0.12 
D5S819 0.21 0.79 0.86 0.00 
D8S88 0.17 0.83 0.88 0.00 
D8S279 0.18 0.82 0.78 0.05 
D8S257 0.33 0.67 0.67 0.00 
D17S578 0.43 0.57 0.68 0.00 
D17S849 0.43 0.57 0.58 0.00 
D17S796 0.27 0.73 0.62 0.15 
This inbreeding coefficient can be interpreted in terms of the 
probability that any two alleles chosen randomly from this 
population are identical by descent from a non-inbred ancestral 
founder i.e. at the point where F was zero (Hartl, 1988). The level 
of heterozygosity obseived was greater than expected in six out 
of ten of the markers. These inbreeding coefficients are recorded 
as zero. 
4S 
3.2.2.2 Homozygosity In the ten selected members 
Homozygosity levels were recorded for all the markers run 
for stages 1, 2 and 3. There were five individuals in each 
of the two categories, affected and non-affected. A 
summary of the results comparing these two categories for 
each chromosome is given in Table 10. The markers for 
chromosome 8 show the highest level of homozygosity in 
the affected individuals with 20.87% compared to 12.17% 
homozygosity in non-affected persons. 
Table 10 Homozygosity levels in the five affected and five non-
affected individuals chosen for the segment sharing method 
Chrom.# Total# markers 
x total# indivs. Homozygotes/chromosome 
Affected Non-affected 
No. % No. % 
1 160 27 16.9 31 19.4 
5 170 15 8.8 15 8.8 
8 230 48 20.9 28 12.2 
9 160 15 9.4 25 15.6 
11 170 22 12.9 15 8.8 
17 110 12 10.9 15 '13.6 
1000 139 27.8 129 25.8 
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3.3 Segment sharing analysis of candidate chromosomes 
Stage 1 : Segment sharing. identification of shared haplotypes 
At this stage haplotypes shared by three or more non-sibling 
chromosomes were identified. These haplotypes were located 
over two adjacent markers at an average distance of 11 cM 
apart. It was also noted at this stage whether or not the affected 
siblings carried the same alleles for these markers. 
Stage 2: Extension of shared haplotypes 
The purpose of this step was to exclude areas in which some of 
the marker alleles coincidentally were the same size in base pairs 
(identical by state - IBS) rather than because they were co­
inherited (ident ical by descent - IBD) from a common founding 
ancestor. This was achieved by running additional polymorphic 
markers internally to the two-marker haplotypes identified at stage 
1. 
Stage 3: Extended pedigree analysis of identified /BD regions 
If the stage 2 markers also formed identical, extended haplotypes 
over three or more non-sibling chromosomes, data were then 
obtained for the extended pedigree. This was achieved by 
running the markers which comprised the identified IBD region for 
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the forty.seven members of the pedigree for whom DNA was 
available. 
The allele assignments were sent to our statistical collaborator 
Joachim Hallmayer at Stanford University, for calculation of the 
LOO scores in order to verify or exclude the proposed linkage 
region. 
3.3.1 Criteria for exclusion 
The criteria for exclusion of regions as identical by state 
(IBS) rather than IBD are as follows: 
*
* 
Extended hap/otypes different
IBD index is O (i.e. zero identical segments shared
by affected sibs)
Recombinations within the extended region
3.3.2 Order of analyses 
Chromosomes known to contain regions or genes 
associated with a form of CMT or myelin protein production 
were first processed. These were chromosomes 1 
(CMT18, CMT2), 8 (CMT4A), 9 (Ciliary Neurotrophic 
Factor Receptor), 11 (Ciliary Neurotrophic Factor) (Lev et
al., 1993; Masu et al., 1993), and 17 (CMT1A). In the 
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event that these chromosomes were excluded, a search of 
the remaining autosomes would be undertaken. 
3.3.3 Markers analysed 
The initial screening process involved the running of 89 
markers on chromosomes 1, 5, 8, 9, 11 and 17. the 
chromosomes which contained candidate genes for CMT 
or PNS proteins. The fraction of the genome which was 
covered totalled 1192 centiMorgans (cM) out of a total 
length of - 3817 cM, that is 31.2°/o. The average distance 
between markers run was 12.6 cM. The breakdown of 
distances per chromosome covered is shown in Table 11. 
Table 11 Distance of genome covered in centiMorgans 
Chromosome Total distance No. of intervals Average distance 
cM cM 
305 23 13.2 
5 233 17 13.7 
8 178 17 10.5 
9 173 14 12.3 
11 155 13 11.9 
17 148 10 14.8 
1192 94 12.6 
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Total genome distance 3817 cM (approximated from Human 
Screening Set Genethon map catalogue: 347 markers at average 
spacing of 11 cM) 
Percentage of genome covered: 1192/3817 x 100 = 31.2% 
Table 12 summarises the details of markers run by giving the 
number of markers which amplified successfully, the number 
which failed to amplify, the number which were uninformative 
(allele origin could not be traced), and the average distance 
between those markers which amplified successfully (including 
those which were uninformative). 
Table 12 Analysis of markers used for Stage 1 screening 
Chrom.# # which gave # which did not # uninformative Average 
results amplify results distance* 
cM 
1 23 1 5 13.2 
5 18 5 4 13.7 
8 15 1 0 10.5 
9 13 1 2 12.3 
11 14 0 0 11.9 
17 11 1 1 14.8 
• This is bet.v.leen markers for which results were obtained
so 
Figure 1 Map distances 
Chromosome 1 
Marker No. Distance Extended region 
015243 
015228 
015214 ScM 
015S07 
015228 ScM 
015436 
24cM 7cM 
015SS2 015483 
7cM 
015233 015482 
015SS2 OcM 
015186 
14cM 
MYCL1 
7cM 
015162 
16 eM 
015SSO 
13 eM 
015207 
14 eM 
018188 
26cM 
015S34 
ScM 
015305 
12cM 
0151167 
13cM 
015318 
ScM 
0151589 
12cM 
015S18 
22cM 
015249 
17cM 
015549 
9cM 
015103 
ScM 
018179 
eM 
015180 
9cM 
015102 
7cM 
Sl 
Figure 2 
Marker No. 
055392 
055406 
055807 
055619 
05542S 
055407 
055427 
055428 
055815 
055409 
0551453 
055421 
055818 
055210 
055820 
Map distances 
Chromosome 5 
Distance 
10cM 
10cM 
25cM 
12 eM 
13cM 
ScM 
2ScM 
ScM 
7cM 
ScM 
7cM 
11 eM 
18 eM 
14cM 
15cM 
055145S 
055408 
GABRA1 
17cM 
30cM 
S2 
53 
54 
Figure 5 Map distances 
Chromosome 11
Marker No. Distance Extended region 
011$1984 
4cM 
011$1988 
12cM 
011$875 
4cM 
011S902 011$904 
3cM 
011$1322 0.8cM 
011S904 011$1312 
10 cM 
011$1392 2.9cM 
011$1301 
2.3cM 
011$1392 
011$1985 
16cM 
011$937 
18cM 
011S876 
8cM 
011$1391 
10cM 
011$976 
15 
011$990 
6cM No extra markers run 
011$912 
18cM 
011$968 
ss 
l6 
From the twenty-four markers run on chromosome 1 (Figure 1), 
one could not be successfully amplified by PCR (D1S248). Five 
markers were uninformative !or these families. In most cases this 
was caused, by homozygosity in both parents. The average 
distance between the successfully run markers was 13.2 cM. 
Twenty-three chromosome 5 (Figure 2) markers were run for the 
forty-seven family members by our collaborators in Sofia. Of these, 
five were unsuccessful and of the remaining markers four were 
uninformative. The average distance between markers was 13.7 
cM. 
On chromosome 8 (Figure 3), sixteen markers were initially run 
with fifteen successful (D8S261 did not amplify). The average 
distance between markers was 10.5 cM. 
On chromosome 9 (Figure 4), fourteen markers were run at an 
average distance of 12.3 cM. One (D9S175) was unable to be 
amplified and two were uninfomnative. 
Fourteen markers were successfully run on chromosome 11 
(Figure 5) at an average distance of 11.9 cM apart. Three markers 
were not run as they were very close to neighbouring markers and 
six were uninformative. 
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Eleven successful markers were run on chromosome 17 (Figure 6) 
at an average distance of 14.8 cM. One marker did not amplify 
(D17S809) and one was situated between two close markers so 
was not run. 
3.3.4 Stage 1 : Identification of shared haplotypes 
Nine regions shared by three or more non-sibling chromosomes 
were identified as possible IBD regions. In order to check whether 
these regions were inherited IBD, they were saturated with a total of 
eighteen additional markers. Figures 1 to 6 illustrate the total 
chromosome, intervals and markers as well as those regions where 
the number of markers has been extended. These regions occurred 
on chromosomes 1p, 8q, 9p, 9q, 11p and 17p. 
Table 13 summarises the segments identified at stage 1 of the 
screening process as those which are shared by three or more 
.· 
affected non-sibling chromosomes. It also records whether there is 
sharing by a sibling and how many copies of each haplotype the 
sibling has inherited. The lack of sharing of the segment between 
siblings is an indication that it is unlikely to be inherited IBD. 
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Table 13 Regions which are shared by at least 3 of 6 (non-sibling) 
chromosomes 
Chrom First Distance 
Marker cM 
1 D1S228 24 
8 08$257 7 
8 08$198 13 
9 D98741 10 
9 09S167 16 
11 D11S904 10 
11 011S990 6 
17 D17S849 16 
Second 
Marker# 
D1S552 
085200 
D88284 
D95319 
D95197 
No. of haplo· Haplotypes 
types shared shared by siblings 
(non·sib) YIN Ped.# Chroms 
4/6 y 13, 49 2 
3/6 y 4,2 2 
4/6 y 13,49/4, 2 2/1 
3/6 N 
3/6 y 13. 49 1 
D11S1392 3/6 y 13,49 1 
D11S912 3/6 y 13. 49 1 
D17S796 3/6 y 4,2 2 
* This indicates whether the affected sibling is homozygous or
heterozygous for the alleles of this haplotype. 
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Figure 7 
D18243 
D1S214 
D18228 
01S552 
D1S233 
MYC!1 
D1$11.:J 
D1S55U 
D1S207 
D1S188 
D1S534 
D1S305 
D1S243 
D1S214 
D1S228 
D1S552 
D18233 
MYCL1 
01$162 
D18550 
D1S207 
D18188 
D18534 
D18305 
Stage 1: Segment sharing results 
Regions shared by three or more non-sibling chromosomes 
Chromosome 1 p 
45 47 
3 3 5 
5 4 3 
4 5 3 
1 1 3 
3 5 6 
3 3 5 
1 4 3 
3 3 2 
•.,.i.' 1 6 
3 2 
1 5 5 
2 2 2 
.---io 
38 42 
3 5 
5 3 
�
3 
3 
3 6 
3 5 
1 3 
3 2 
5 6 
3 2 
1 5 
2 2 
5 
4 
4 
1 
4 
3 
6 
2 
4 
2 
2 
1 
I • 
13 
3 3 
3 5 
[I] [] 
3 5 
3 2 
4 6 
4 3 
2 4 
4 4 
4 2 
1 2 
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10 3 1 
3 3 5 3 5 
5 1 3 5 4 
4 4 3 3 4 
1 1 3 3 2 
5 1 5 2 5 
2 3 3 1 3 
6 2 1 ·1 7 
3 3 3 3 3 
4 4 5 4 2 
4 3 7 ? 4 
2 5 1 5 3 
2 1 1 3 2 
i 
49 4 2 
3 3 5 5 5 
3 1 3 4 3 
4 4 3 4 3 
1 1 3 2 3 
4 1 5 5 5 
4 3 3 3 3 
5 2 1 7 1 
4 3 3 3 3 
6 4 5 2 4 
4 4 ? ? 4 
4 5 1 3 5 
2 1 1 2 3 
2 
5 
4 
1 
3 
2 
6 
1 
3 
1 
5 
1 
5 
4 
[] 
5 
3 
.... 
2 
4 
3 
2 
Figure 8 Stage 1 : Segment sharing results 
Chromosome1q 
45 47 10 3 1 
0151167 3 1 4 3 2 4 1 4 2 5 
0151589 4 3 1 4 4 2 2 4 2 4 
015518 1 4 2 2 1 4 4 4 2 3 
015249 1 4 3 6 6 2 6 6 2 5 
015549 3 1 1 1 3 2 2 3 3 2 
015103 5 4 1 3 3 1 5 3 4 4 
O'S102 2 2 3 1 2 3 3 3 2 2 
• 
[j 
38 42 13 49 4 2 
0151167 3 4 2 2 4 2 1 2 4 5 
0151589 4 1 4 4 4 2 2 2 2 4 
015518 1 2 4 1 1 1 4 2 4 3 
015249 1 3 1 6 1 6 6 2 6 2 
015549 3 1 1 3 1 3 2 3 2 2 
015103 5 1 2 3 2 3 5 4 5 4 
015102 2 3 3 2 3 2 3 2 3 2 
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Figure 9 Stage 1 : Segment sharing results 
Chromosome 5 
DTD 
45 47 10 3 1 
055392 2 4 5 2 3 2 4 3 2 3 
055406 4 5 5 3 4 5 1 3 1 5 
055807 4 1 5 4 4 5 1 1 5 1 
055819 5 3 1 4 4 3 4 5 2 4 
055426 3 4 4 5 5 4 4 5 5 1 
055407 4 4 4 2 3 2 5 3 2 3 
055427 4 4 2 2 5 1 5 1 2 1 
055428 2 2 1 1 2 3 2 3 2 1 
055815 6 6 8 7 B 3 5 5 6 4 
055409 3 1 2 3 3 3 3 1 3 2 
0551453 5 1 3 5 5 6 1 5 1 1 
056421 5 5 3 6 5 4 7 4 1 6 
056818 3 3 3 3 4 3 3 2 2 2 
056210 4 1 6 4 7 4 1 4 ? ? 
056820 2 4 4 3 4 3 1 3 3 4 
0561456 5 4 5 1 2 4 4 5 4 3 
GABRA1 3 3 5 3 5 2 2 6 2 3 
38 42 13 49 4 2 
055392 4 2 2 3 5 3 4 3 4 3 
056406 5 3 3 4 3 4 1 5 1 5 
056807 1 4 3 4 3 4 1 1 1 1 
056819 3 4 5 4 5 3 4 2•' 4 4 
055426 4 5 5 5 5 5 4 5 4 1 
056407 4 2 4 3 4 3 5 2 5 3 
056427 4 2 '1 5 5 5 ? ? 5 1 
055428 2 1 1 2 1 3 2 2 2 1 
055815 6 7 5 8 5 3 ? ? 5 4 
055409 1 3 2 3 2 3 3 3 3 2 
0561453 1 5 ? ? 1 5 1 1 1 1 
056421 5 6 5 5 4 5 7 1 7 6 
056818 3 3 2 4 2 4 3 2 2 2 
056210 1 4 4 7 4 7 1 4 1 4 
D5S820 4 3 2 4 2 4 ? ? 1 4 
0561456 4 1 3 2 3 4 4 3 5 3 
GABRA1 3 3 2 5 2 2 2 3 6 3 
"' Phase unknown 
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Figure 10 Stage 1 : Segment sharing results 
Regions shared by three or more non-sibling chromosomes 
Chromosome 8 
o-ro JZh-o 
45 47 10 3 1 
088254 5 5 3 4 3 2 3 1 3 5 
085439 1 3 2 2 5 4 2 2 4 1 
088265 1 3 3 3 4 4 4 5 1 4 
088136 4 4 4 2 4 3 2 1 2 3 
08887 1 3 3 3 2 3 1 1 3 3 
0851110 4 1 5 2 4 2 2 5 2 4 
0881113 1 1 2 4 2 1 4 2 2 2 
085279 10 10 1 4 9 8 7 2 10 9 
08888 1 6 8 6 6 6 5 4 7 6 
085257 4 2 4 4 4 3 4 4 4 4 
085200 2 3 6 4 4 4 2 5 2 2 
088199 2 1 6 3 4 2 2 4 5 3 
088198 3 4 3 2 3 3 3 4 3 3 
088284 8 12 3 11 3 2 2 1 3 2 
085272 2 3 2 2 1 2 2 3 2 2 
085373 3 3 2 4 2 3 4 2 3 2 
I ~ • 38 42 13 49 4 2 
085264 5 3 2 3 2 3 3 '3 3 3 
0854"$9 1 2 1 5 3 5 2 4 2 4 
085265 1 3 2 4 3 4 4 1 5 1 
085136 4 4 2 4 2 4 2 2 1 3 
08587 1 3 2 2 2 *3 1 3 1 3 
0851110 4 5 3 4 3 2 2 2 5 4 
0851113 1 2 *1 2 3 1 4 2 2 2 
085279 10 1 7 9 3 9 7 10 7 10 
08588 1 8 1 6 5 6 5 7 5 7 
085257 [iJ 4 4 4 4 4 [;] ~ 4 4 085200 6 4 4 5 4 2 2 
085199 2 dJ [i] m 3 4 2 5 2 5 085198 3 3 3 3 rn 3 3 088254 8 3 3 2 2 3 
088272 2 2 1 1 1 1 2 2 2 2 
088373 3 2 1 2 1 2 4 3 4 3 
• Phase unknown 
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Figure 11 Stage 1 : Segment sharing results 
Regions shared by three or more non .. sibling chromosomes 
Chromosome 9 
Gr{) 
45 47 10 3 1 
09$178 3 3 1 3 3 3 3 2 3 4 
09$168 3 3 2 2 2 2 1 3 4 1 
09$156 2 3 3 1 4 4 1 4 3 4 
09$741 3 3 3 3 4 1 3 3 2 1 
09$319 1 1 2 2 1 2 2 1 2 2 
09$301 2 2 4 3 5 1 5 2 5 2 
09$303 4 4 2 3 5 4 3 4 2 1 
09$167 5 3 4 2 5 5 1 4 1 5 
09$197 1 3 2 1 1 1 4 1 1 1 
09$299 2 3 1 3 3 1 1 2 3 3 
D9S105 2 3 4 1 4 3 4 4 2 2 
09$302 4 2 2 2 4 3 4 1 1 5 
D9S159 3 2 2 1 2 2 2 3 3 1 
I • 
38 42 13 49 4 2 
D9S178 3 1 3 3 3 3 3 3 2 
09$168 3 2 2 2 3 2 1 4 3 
D9S156 2 3 3 4 1 4 1 3 4 
D9S741 3 [] .[1] 4 2 4 [] 2 3, 09$319 1 1 1 1 2 1 
D9S301 2 4 3 5 3 5 5 5 2 
D9S303 4 2 3 5 3 4 3 2 4 
098167 
[TI 
4 1 [TI 1 5 1 1 4 D98197 2 4 4 1 4, 1 4 
D9S299 2 1 ·1 3 3 3 1 3 1 
D98105 2 4 •3 4 3 4 4 2 4 
098302 4 2 •3 4 2 3 4 1 1 
D98159 3 2 3 2 3 2 ? ? 3 
• Phase unknown
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Figure 12 Stage 1 : Segment sharing results 
Regions shared by three or more non�sibling chromosomes 
Chromosome 11 
.D-TO 
� 
45 47 10 3 1 
D1181984 4 6 4 3 3 2 5 4 1 4 
D11S988· 1 1 3 1 2 1 4 1 4 4 
D11S875 2 3 3 2 2 2 2 4 4 1 
D115902 3 5 2 1 3 4 2 1 2 4 
D11S904 5 1 2 2 5 1 2 4 5 5 
D1181392 4 4 3 4 4 2 2 1 3 4 
D1151985 5 1 7 6 5 5 4 3 6 1 
D11S937. 4 3 3 3 1 1 4 2 4 4 
D11S876 5 1 4 2 2 2 4 4 4 3 
D11S1391 2 4 1 4 2 2 ? ? 2 2 
D11S976 6 2 2 4 3 4 5 2 ? ? 
D11S990 1 4 1 3 2 1 4 2 1 5 
D11S912 3 4 4 1 3 2 4 2 4 4 
D11S968 3 2 1 2 4 1 4 2 2 2 
I n 
38 42 13 49 4 2 
D11S1984 4 4 2 3 3 3 5 1 4 1 
D115988 1 3 •1 2 1 2 4 4 1 4 
D11S875 � 3 4 2 4 2 2 4 4 4 
D11S902 
[D 
2 1 3 1 3 2 2 1 4 
D11S904 2 ·1 [] 1 5 2 5 4 [] D11S1392 3 2 2 4 2 3 1 
D11S1985 5 7 8 5 2 5 4 6 3 1 
D11S9:37 4 3 ' 1 1 1 1 4 4 2 4 
D11S876 5 4 2 2 .  4 2 4 4 4 3 
011$1391 2 1 3 2 4 2 1 2 1 2 
011$976 6 2 
·rb 
3 2 3 5 
� 
5 5 
D11S990 1 [] 2 1 2 4 4 5 0116912 3 3 4. 3 4 2 4 
0116968 3 1 4 4- 2 4 4 2 2 2 
• Phase unknown
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Figure 13 Stage 1 : Segment sharing results 
Regions shared by three or more non-sibling chromosomes 
Chromosome 17 
45 47 10 3 1 
D17S578 4 3 3 3 4 3 3 2 4 3 
D17S849 2 2 ? ? 1 1 2 2 2 2 
D17S796 5 4 1 2 5 1 5 3 5 5 
D17S520 3 1 3 5 2 5 3 2 4 4 
D17S799 4 3 3 3 4 3 3 3 4 3 
D17S122 4 2 3 5 3 5 4 2 3 2 
D17$798 2 2 3 5 5 2 3 2 3 3 
D17S579 4 1 2 3 1 6 4 1 6 3 
D17S795 5 3 5 5 4 3 4 3 6 6 
D17S785 7 6 5 7 5 6 7 7 7 3 
D17S784 4 3 2 3 3 3 6 3 4 2 
n • • 
38 42 13 49 4 2 
D17S57B 4 3 *3 4 3 3 3 4 3 4 
D17S849 l� 1 1 1 4 1 gJ rn 2 2 D17S796 1 3 5 3 5 6 5 
017$520 3 3 4 2 4 5 2 4 2 4 
017$799 4 3 "'3 4 3 3 3 4, 3 4 
D17S122 2 3 4 3 4 5 2 2 4 2 
D17S798 2 5 *2 5 2 2 3 3 3 3 
017$579 1 2 1 1 4 6 1 3 1 3 
017$795 3 5 5 4 6 4 4 6 3 6 
017$785 7 5 3 5 5 "'6 7 3 7 3 
D17S784 4 3 4 3 4 3 3 4 6 4 
• Phase unknown
Figure 7 shows the alleles for the thirteen markers run on 
chromosome 1p. It highlights the 24 cM region between D1S228 
and D1S552 which is common to four out of six non-sibling 
chromosomes. D1S228 is uninformative in two of the families and 
D1 S552 is uninformative in the family where t,10 of the three 
identical flanking alleles were identified. Affected sibling 49, 
although showing the same haplotype for these two markers, has 
inhertted a different maternal chromosome. Number 2 has a double 
recombinant maternal chromosoma in the region (24 cM). 
Figure 8 shows the results for chromosome 1 q. There were no 
more than 2/6 shared haplotypes on this arm of chromosome 1. 
The data for chromosome 5 is presented in figure 9. However, 
there were no segments shared by more than two out of six non­
sibling chromosomes. 
Figure 10 gives the results of the initial set of marker loci run the 
length of chromosome 8. Two regions of sharing were found, one 
with flanking markers D8S257 and DBS200 (a distance of 7 cM) and 
another between DBS198 and D8S284 (a distance of 20 cM). 
These two segments are separated by 11 cM. 
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Figure 11 gives the results for markers run on chromosome 9 
where two separate regions are shared between three of six non-
sibling chromosomes. The first region, on 9p, is a 10 eM segment 
between markers 098741 and 098319. Both markers are 
uninformative. No affected siblings share this region. 
The second region on 9q between markers 098167 and 
098197 covers 17 eM. Only one affected sibling (number 49) 
has this haplotype from the maternal triple recombinant 
chromosome. The segment may be from the same chromosome 
as number 13, however it is not clear at which point the second 
crossover occurred (i.e. either between 098303 and 098167 or 
between 098197 and 098299). 
Figure 12 gives the results for the original fourteen markers run 
on Chromosome 11. It highlights two regions which showed 
sharing of haplotypes in three of six non-sibling chromosomes. 
The first on 11p was between markers 0118904 and 
01181392, a 10 eM region. Affected sibling 49 has inherited 
the same maternal chromosome as his affected sister. Affected 
sibling 4 has inherited a different maternal chromosomal 
segment in this region. 
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Chromosome 17 results are shown in figure 13. A 16 eM segment 
Is shared by 3/6 non-sibling chromosomes and numbers 4 and 2 are 
homozygous for both these flanking marker loci. The first marker, 
0175849, is uninformative. 
3.3.5 Stage 2 : Detailed analysis of shared haplotypes 
Exclusion of stage 1 haplotypes is summarised in Table 14. 
The IBD index refers to the number of identical haplotypes 
shared by affected siblings, such tha! a 0 indicates that no 
sibs have the same segment, and a 1 or 2 indicates that a sib 
has the same haplotype on either one or two chromosomes. 
Exclusion results when either one of the following criteria is 
met: 
the extended haplotype is different 
the IBD index is zero or one 
69 
Table 14  ExcJusion criteria for Stage 1 segment sharing
Chrom.# IBD Extended Excluded 
index haplotype 
0·2 identical yin 
1 2 n y 
8 2 y n 
9 0 n y 
9 1 n y 
11 1 n y 
17 1 y* 
* The region on chromosome 17 was excluded by LOD score
analysis prior to commencement of the segment sharing method, as 
it is a candidate gene region. Extra markers were not run. 
The results of the stage 2 detailed screening follow with figures 14 
to 18 showing the haplotypes for the ten selected members. 
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Figure 14 Stage 2: Segment sharing results 
Detailed analysis of shared haplotypes 
Chromosome 1 p 
45 47 10 
015228 5 4 3 4 4 4 
015507 4 5 1 2 5 5 
015436 3 6 7 2 8 7 
':>15483 3 1 1 3 1 3 
015482 4 4 4 4 1 2 
015552 1 1 3 1 1 1 
38 42 13 49 
015228 4 3 4 4 4 4 
015507 5 1 1 5 1 5 
015436 6 7 .7 B 7 7 
015483 1 1 1 1. 1 3 
015482 4 4 3 1 4 2 
015552 1 3 1 1 1 1 
* Phase unknown 
3 'I 
3 3 4 4 
2 4 2 3 
4 5 1 3 
1 1 2 1 
1 2 4 4 
3 3 2 1 
4 2 
3 4 3 4 
4 2 4 3 
5 1 5 3 
1 2 1 1 
2 4 2 4 
3 2 3 1 
•• Exclusion of IBD because the haplotypes within the original (highlighted in bold) 
markers are not identical. 
-original marker 018228 is uninformative in the families (10,131~ 49) and 
(1,3,4,2), and 015552 is uninformative in family (10,13 & 49) which is where 216 
chromosomes were first identified. 
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085198 
085263 
085284 
085198 
085263 
D85284 
Figure 15 Stage 2 Detailed analysis of shared haplotypes 
Chromosome 8q 
45 
3 4 
4 3 
8 12 
38 
3 3 
4 1 
8 3 
3 
1 
3 
47 
2 
4 
11 
42 
3 
1 
3 
13 
3 
1 
3 
3 
1 
3 
3 
1 
3 
10 3 1 
3 3 4 3 3 
4 1 4 4 2 
6 2 1 3 2 
49 
3 
1 
3 
3 
1 
2 
3 
4 
3 
3 3 
1 4 
2 3 
Extended region still shared by 3/6 non-sib chromosomes. Identical region shared by sibs 
13 & 49. 
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Figure 16 Stage 2 : Detailed analysis of shared segments 
Chromosome 9p 
095161 
095741 
095165 
095319 
095161 
095741 
095165 
095319 
4 
3 
4 
1 
4 
3 
4 
1 
*Phase unknown 
45 
36 
47 
5 3 
3 3 
4 2 
1 2 
3 
3 
2 
2 
3 
3 
2 
2 
42 13 
1 
3 
3 
.2 
4 
4 
4 
1 
4 
4 
4 
1 
10 
49 
4 
2 
2 
1 
3 
3 1 
1 3 
4 4 
2 2 
4 
4 1 
4 3 
4 4 
1 2 
1 
4 2 4 
3 2 1 
2 1 4 
1 2 2 
2 4 
2 3 
1 2 
2 1 
2 
Extended region reduces to below threshold with 0/61dentlcal non·sibling 
haplotypes. 
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Figure 17 Stage 2 : Detailed analysis of shared haplotypes 
095167 
095283 
095197 
5 
4 
1 
45 
Chromosome 9q 
47 
3 2 4 
5 3 3 
3 1 2 
38 42 
095167 
095283 
095197 
5 
4 
1 
* Phase unknown 
4 
3 
2 
1 
.2 
4 
5 
5 
1 
10 
5 
2 
1 
5 1 5 
5 2 5 
1 4 1 
1 
4 
4 
1 
4 
4 
3 
1 
2 
1 
1 4 
2 4 
1 4 
1 
Extended region reducas to below threshold with 216 identical non-sibling haplotypes 
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1 
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Figure 18 Stage 2 : Detailed analysis of shared haplotypes 
Chromosome 11 
45 47 10 3 
011$904 5 1 2 2 5 1 2 4 5 
011S1322 4 1 4 2 4 3 4 4 4 
01181312 4 4 4 2 4 2 3 4 1 
011$1301 2 3 3 2 4 3 2 2 2 
011S1392 4 4 3 4 4 2 2 1 3 
1 
n C 
38 42 13 49 4 2 
011S904 5 2 1 5 1 5 2 5 4 
011S1322 4 4 1 4 1 4 4 4 4 
011S1312 4 4 4 4 4 4 3 1 4 
011S1301 2 3 2 4 2 4 2 2 2 
011$1392 4 3 2 4 2 4 2 3 1 
5 
1 
4 
1 
4 
5 
1 
4 
1 
4 
The three original haplotypes when extended each show a different internal set of 
alleles. 
Sibs have different haplotypes except for 13 & 49. 
7S 
Figure 14 shows an expanded view of this 24 eM shared 
region on chromosome 1 p with four extra markers run between 
018228 and 01 8552 at an average distance of 6 eM. Each 
one of the four expanded haplotypes is different over the 24 
eM. However, three of six common haplotypes over three 
markers 018483, 018482 and 018552 are shown (7 eM 
region). Results from the region 018483 to 018482 (also 7 
eM as 018482 and 01 S552 are shown at the same map 
locus) show four out of six non-sibling chromosomes with the 
1 ,4 and 3/6 with the 1 ,4, 1 haplotype in pedigree members 38, 
49 and 2. These two 7 eM segments (1 ,4 or 1 ,4, 1) are not 
shared by sibling number 4 who has inherited the other 
maternal chromosome with a recombination outside the region. 
They are not shared by affected sibling 13 as 49 has inherited 
a recombinant paternal chromosome where the crossing-over 
occurred in the middle of this 7 eM segment. Phase is unknown 
for 13 at marker locus 018436 and for 49 at marker 018483 
(one of the 7 eM shared 1,4 haplotypes). There are only three 
alleles for each of the flanking markers D1 8483 and D1 8552 of 
the 7 eM shared haplotype. 
Figure 15 shows the extended haplotypes for 088198 to 
088284. The extended region still showed sharing by 3/6 non-
sibling chromosomes with an identical region shared by 
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siblings 13 and 49 on both chromosomes. Numbers 4 and 2 
also have this region IBD, although with different haplotypes. 
Figure 16 gives the results for the 9p region between D9S161 
and D9S301. The only available marker between D9S741 and 
D9S319 was D9S165 at 6 cM telomeric to D9S741. However, 
D9S161 was close to the region at 2 cM centromeric to 
D9S741 so this was run also. These markers did not show 
more than two of three common haplotypes. 
On 9q two extra markers, D9S283 and D9S318, were run 
between D9S167 and D9S197 but D9S318 did not amplify. 
This left D9S283 at a distance of 10 cM telomeric to D9S167. 
The results from these investigations are shown in figure 17. 
Even though phase is unknown for members 13 and 49 for 
marker D9S283, reversing the allele order still would not result 
in more than two common haplotypes. 
The second region was on 11q between D11S990 and 
011 S912, a distance of 6 cM. One affected sibling (number 
49) has also inherited the same alleles for these flanking
markers. The results of three extra markers, D11S1322, 
D11S1312 and D11S1301, run between markers D11S904 
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and D11S1392, at an average distance of 2.5 cM, are shown in 
figure 18. Two identical haplotypes over a distance of 3.8 cM 
were seen between D11S904 and D11S1312. Four non­
sibling chromosomes show the 4,4 haplotype between 
D11S1322 and D11S1312 which are 0.8 cM apart. No extra 
marker was run in the second region between 011 S990 and 
D11S912 covering 6 cM on 11q. Siblings 13 and 49 share the 
same haplotype although it may be from the other paternal 
chromosome. 
Table 15 summarises the sharing patterns in the extended 
regions. It shows that only the two chromosome 8 regions 
(separated by 11 cM) remain with 3/6 identical non-sibling 
chromosomes. 
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Table 15 Sharing patterns in extended regions 
Chrom First Distance Second No. of haplo-
types shared Shared by siblings 
No. Marker#. cM Marker# by non-sibs 
YIN Ped.# No.Chroms 
1 D1S228 5 D1S507 2/6 y 13,49 1 
01S507 5 01S436 216 y 13,49 1 
D18436 7 D1S4B3 216 y 13, 49 1 
D1S4B3 7 01S482 4/6 N 
01S482 0 01S552 3/6 N 
Total extended haplotype 0/6 
8 DBS257 7 08$200 3/6 y 4, 2 2 
DSS198 15.4 DBS263 3/6 y 13, 49 2 
D88263 4 08S284 3/6 y 13,49 2 
Total e>..tended haplotype 3/6 
9 098161 2 098741 2/6 N 
D9S741 6 09$165 2/6 N 
D9S165 4 D9S319 2/6 N 
Total extended haplotype 0/6 
9 095167 10 D9S2B3 216 y 13,49 1 
D9S283 7 098197 2/6 y 13, 49 1 
Total extended haplotype 2/6 
11 011S904 3 011$1322 3/6 y 13,49 1 
011$1322 0.8 01181312 4/6 y 13, 49 1 
011$1312 2.9 011$1301 3/6 y 13,49 1 
011S1301 2.3 011$1392 216 y 13,49 1 
D11S990 6 011S912 3/6 y 13,49 1 
Total extended haplotype 0/6 
17 017S849 16 D17S796 3/6 y 4,2 2 
" Two different haplotypes 
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3.3.6 Stage 3: Extended pedigree analysis of IBD region 
The next stage involved running the whole family against the three 
markers in the region. These data were transmitted to Joachim 
Hallmayer at Stanford for analysis using the computer program 
Fastlink. Nuclear families were treated as separate and the results 
combined. These results are shown in Table 16. Theta (0) represents 
the recombination fraction or the genetic distance between the marker 
locus and the disease gene locus. 
Table 16 Two point LOD scores for IBD region on Sq 
Recombination fraction (0) 
Locus 0.0 0.05 0.1 
Published allele frequencies (GDB) 
D88198 -3.09 -0.38
D8S263 -0.85 0.57 
DSS284 3.41 2.93 
Equal allele frequencies 
D8S198 
D8S263 
08S284 
-3.09 
-0.60 
3.44 
-0.38
1.02
2.96
80 
-0.03
0.70
2.45
-0.12
1.06
2.48
0.15 
-0.02
0.66
1.98
-0.03
0.94
2.00
0.2 
-0.04
0.55
1.52
-0.02
0.77
1.54
Due to the increasing lod scores approaching marker D8S284, and the 
significant score at this locus, additional markers were obtained from 
Research Genetics for the region between D8S284 and D8S27 4. The 
extended haplotypes for the segment sharing members between 
marker loci D8S198 and D8S274 are shown in figure 19. 
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Figure 19 Stage 4 : Fine mapping the region of interest by further 
extension of haplotypes 
Chromosome Bq 
45 47 10 3 
085198 3 4 3 2 3 3 3 4 3 
085163 4 3 1 4 1 4 1 4 4 
085284 8 12 3 11 3 6 2 1 3 
08555a 1 6 6 5 6 4 6 4 6 
085557 4 3 2 3 6 2 3 6 1 
085529 8 8 8 3 a 7 8 8 8 
085256 8 8 5 2 5 6 8 2 8 
OaS537 a 7 1 5 4 4 8 2 7 
085554 5 2 2 3 3 3 5 4 4 
085272 2 3 2 2 1 2 2 3 2 
085274 5 2 3 5 4 3 5 3 4 
38 42 13 49 4 
08519a 3 3 3 3 3 3 3 
oa5263 4 
LcM ~ ~ 1 ~ 1 OaS2a4 8 2 2 08S55a 1 6 6 
oa5557 4 2 2 6 6 6 
OaS529 a a a a a 8 
085256 a 5 5 5 5 5 a 8 8 
085537 8 1 4 4 4 4 8 7 8 
085554 5 2 3 3 3 3 5 4 5 
DBS272 2 2 1 1 1 1 2 2 2 
085274 5 3 4 4 4 4 5 4 5 
EXtended haplotype 3,1,3,6,2,8 (over 27 eM) still shared by 3/6 non sib chromosomes 
EXtended haplotype shared by sibs 13 & 49 
Haplotype 3,6 between 085284 and 085558 Is shared by 4/6 non-sib chromosomes, 
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3 
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2 
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The two point lod scores for these additional markers are listed in Table 17. 
These results are based on a pedigree structure with connections between 
families 2 and 3 as well as the branch containing numbers 14 and 26. 
Table 17 Two point LOD scores for fine mapping of lBO region on 8q 
Recombination fraction (9) 
Locus 0.0 0.05 0.1 0.15 0.2 
Equal allele frequency; 0.05 disease gene frequency 
088284 -infinity 2.23 1.95 1.57 1.19 
088557 1.83 1.93 1.69 1.39 1.09 
088558 3.38 2.81 2.2: 1.83 1.41 
088529 2.73 2.30 1.88 1.47 1.10 
088256 2.29 2.41 2.09 1.69 1.28 
088537 1.88 1.94 1.69 1.38 1.07 
The different led scores at locus 088284 between the initial 
calculations and these later results reflects the different treatment of 
the pedigree within the Fastlink program in terms of inter-family 
connections. In Table 16 the nuclear families were treated as 
separate (apart from linked branches family numbers 2 and 3) and the 
rE•sults summed. In the later calculations, additional links were 
Included. 
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Haplotypes formed from marker loci DBS263, 08S284, DBS558, 
DBS557, DBS529 and DBS256 for the extended pedigree follow in 
figures 20 to 23. Map distances according to the CEPH map (GOB) 
are: 
DBS263 to D8S284 2cM 
DBS284 to DBS558 3 cM 
DBS558 to D8 557 0 cM 
DBS557 to DBS529 1 cM 
D8S529 to DBS256 2 cM 
The full pedigree was split into separate nuclear families numbered 1 
to 6. This is reflected in the original numbering system where the 
family number precedes the individual number e.g. 2-5 (Appendix D 
shows both sets of numbers). A total of six different mutant 
haplotypes were identified in this region and these are highlighted by 
colours so that the inheritance pathways can be traced., 
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CHAPTER 4. DISCUSSION & CONCLUSION 
A locus for a previously undescribed autosomal recessive form of 
CMT has been mapped to a 27 cM region 8q24.13-qter using a 
relatively new approach to rapid genome screening, namely segment 
sharing. The method is based on the identification of identical 
chromosomal segments shared among distantly related members of a 
population exhibiting random inbreeding. Subsequent lod score 
analysis places the candidate gene in the region between markers 
08S557 and 08S256, a distance of 3 cM. 
Stage one of this rapid genome screening method resulted in the 
identification of eight regions flanked by markers at an average of 
13.7 cM apart. These shared regions were on chromosomes 1, 8, 9, 
11 and 17. Stage two, the detailed analysis of these haplotypes, 
excluded identity by descent (IBD) in all but one region. For this 20 
cM region, located on Bq, sharing of alleles IBD was confirmed over 
the extended region for three out of six non-sibling chromosomes. 
Using the results of the formula for p2 in Table 4, the probability of a 
false positive result over a segment of this length being found in three 
out of six chromosomes had been estimated at 1.2 x 10"10• The 
validity of these findings was confirmed by conventional linkage 
analysis of th!) extended pedigree. The maximum lod score for the 
region was obtained for 08S558, 3.38 at zero recombination. As time 
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permits, more markers will be run In the interval DBS557 to DBS526 to 
reduce the linkage region. 
In order to gain an indication of the underlying genetic structure of this 
population, In particular the level of genetic heterogeneity and 
inbreeding, a sample of ten unlinked markers was examined. These 
markers were on four chromosomes and they were run for the 
extended pedigree. The first aspect examined was the actual number 
of alleles compared to those published for CEPH families. The total 
number of alleles over 9 of the markers (for one the published number 
of alleles was not listed) in the actual sample was 32.6% less than the 
published number. This seemed to be in keeping with the 
expectations for an inbred, isolated population (i.e. a restricted gene 
pool with incr eased homozygosity). To follow through on this 
hypothesis the heterozygosity indices were calculated and compared 
to those published for the CEPH families. In four of the ten markers 
the observed heterozygosity was higher than published and for 
another two markers the difference was within 0.04. Inbreeding 
coefficients were positive in only three of the ten markers. However, 
two of these were higher than would be expected at 0.12 and 0.15. 
For one of these markers (D176796) this is due to a high number of 
homozygotes for the highest frequency allele. 
Overall the level of inbreeding for the population is extremely low (at 
eight decimal places it was still zero), even though there are many 
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connections between affected branches of the kindred. This low level 
of Inbreeding, as well as the ca(cuiated disease gene frequency of 
0.08 in the population of 2000 Bulgarian Gypsies, directed the study 
away from homozygosity mapping and towards the segment sharing 
approach. 
The outcome of this study, that is linkage of the gene for this 
autosomal recessive CMT, was successful. The region identified as 
180 was linked to the disease gene. For the 31% of the genome 
covered, the segment sharing method did not produce any false 
positive 180 regions. The screening of only ten members was an 
efficient and time-saving facet of the method. However, further 
reduction in the second stage screening may be possible. For the 
purposes of a rapid screening method, the question arises of whether 
it is efficient to continue to stage two for those regions which can be 
excluded without extending the haplotypes. One criterion which 
could be applied for exclusion at Stage 1 is: 
• affected sibs do not share the same haplotype.
If it is assumed that the segment is 180, these regions would be 
unlikely to be linked to the disease gene. This would not be the case 
if two or more different mutations existed at the same locus or more 
than one disease locus was present. However, in these cases the 
power to detect 180 is reduced and so the choice of this method may 
be inappropriate. For this reason, the choice of method is influenced 
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by the structure and age (since founding) of the population under
investigation, in addition to the disease gene frequency.
The correct choice of individuals and knowledge of possible 
relationships within the population is one pre-requisite to the success 
of the method. In our case, it might perhaps be suggested that good 
fortune was another, since alternative choices of individuals and/or 
polymorphic markers in this study could have resulted in the Sq region 
being overlooked at Stage 1 screening. As an example, the 
individuals selected could have been numbers 26, 36 and 4. Number 
36 is related to 26 over a 7 step pathway, 36 related to 4 over two 
pathways one 7 step and one 9 step (minimum is used), and 26 is 
related to 4 via 9 steps. The choice of these members would have 
resulted in an average of 7.6 meiotic events separating the individuals 
by comparison with 9.4 for the actual individuals selected. Numbers 
13 and 36 were not considered as they are first cousins (a five step 
pathway) and as such, share 1/16 of their genes. The, kinship 
coefficients for various combinations of individuals showed that the 
degree of relationship between the alternatives 36 and 26 was 0.016, 
the same as that between 13 and 4. Although 4 and 26 were closer 
than those selected the difference between coefficients was only 
0.002. 
In theory, the more distantly related Individuals were better choices 
due to the reduced chance of JBS sharing. However, for this project 
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the selection of individuals proved to be invalid since, when the full 
results were obtllined for the forty-seven members in the 8q "IBD' 
region, it was discovered that some of the shared haplotypes were not 
transmitted along the expected common ancestor pathways. 
The shared region between marker loci D8S198 and D8S256 (Figure 
19) identified in three of the six non-sibling chromosomes (in numbers
38 and 13), appeared to be IBD. However, one mutant haplotype 
can only be traced from 38 to maternal grandfather and it is not known 
whether it was transmitted via the expected route of great­
grandmother with links to the other branches, or if it was transmitted 
from the maternal great-grandfather with no known connections. This 
was the case for number 4 where one mutant haplotype was not 
transmitted via the expected route (through individual number 90) but 
instead came from the paternal great-grandmother who has no l;nown 
links with 38 and 13. The second mutant haplotype was transmitted 
to number 4 by maternal great-grandfather number 33 rather than via 
number 30 who also has no known links with 38 and 13. 
These examples highlight the problems with using this method for 
such a randomly inbred pedigree. A total of six different mutant 
haplotypes were identified in the twelve affected individuals. To have 
this number of recombinants the mutation/s must have been 
introduced into the population a long t ime ago and most probably by a 
number of carriars. 
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Would the alternative choices have given a truly IBD region? Numbers 
36 and 26 share one identical haplotype - 26 via the paternal 
grandmother and 36 via the paternal grandfather. However, 36 and 4 
do not share any identical haplotypes, as the mutant chromosomes 
inherited by 4 have come from individuals (2-4 and 33) whose 
connections within the pedigree are unknown. With hindsight it is 
apparent that there was no ideal choice of individuals for the segment 
sharing method in this pedigree. Although the desired result was 
obtained, i.e. localising the disease gene for this form of CMT, it was 
not as a result of the applicability of the segment sharing method. 
The linkage analysis performed for the extended pedigree served to 
reinforce the IBD finding on 8q with the 3/6 shared haplotypes giving 
maximum lod scores for D88198 of 0.02 at 15% recombination, and 
for D88284 of 3.41 at zero recombination. This positive indication of 
linkage for D88284 was strengthened by running more markers 
telomeric to this marker. This second group of lod scores gave a 
different result for D88284 at zero recombination, minus infinity, 
because of extra inter-family connections being included in the 
calculations. Originally the results were calculated and summed for 
th?. nuclear families as though they were unrelated. The results of 
analysis of the pedigree including the links between families 2 and 3 
and individuals 14 and 26 gives a maximum lod score of 3.16 at 5% 
recombination for marker D88284. A maximum lod sco.-e of 2.73 at 
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zero recombination was obtained for the marker DBS529, 3.5 cM 
telomeric to DBS284. The next three markers telomeric to DBS529 
show decreasing lod scores, an expected trend. Therefore the most 
likely placement of this new CMT disease gene is between markers 
D8S284 and DBS529. This is only a relative genetic map position as 
placement of these markers has not been physically confirmed. 
9S 
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cM 
CMT 
CNTF 
DNA 
dCTP 
dNTP 
dUTP 
EDTA 
HMSN 
HNPP 
180 
LOO 
MCV 
MPZ 
OD 
PAGE 
PCR 
PMP2 
PMP22 
TBE 
TEMED 
LIST OF ABBREVIATIONS 
Centi-Morgan 
Charcot-Marie-Tooth 
Ciliary neurotrophic factor 
Deoxyribonucleic acid 
Deoxycytosine triphosphate 
Deoxynucleotide triphosphate 
Deoxyuridine triphosphate 
Ethylenediaminetetraacetic acid 
Hereditary motor and sensory neuropathies 
Hereditary neuropathy with pressure palsies 
Identical by descent 
Logarithm of the odds 
Motor nerve conduction velocity 
Myelin protein zero 
Optical density 
Po lyacrylamide gel electrophoresis 
Polymerase chain reaction 
Peripheral myelin protein 2 
Periphera l myelin protein 22 
T ris-Borate-EDTA 
Tetramethylethylenediamine 
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APPENDIX B 
IOS 
·Full pedigree Bulgarian Gypsies (a)
106 .· 
Full pedigree Bulgarian Gypsies (b) 
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,_. 
0 '° 
Subset of pedigree Segment Sharing 
32 
GYPSY CMT FAMILY: DNA CONCENTRATIONS 
Family Ped# Link# Concentration Dilution 
ng{J.ll 1 OJ.LIDNA + ..• H2 
! 
1 99 2 197 187 
1 96 4 294 284 
1 20 5 647 637 
1 91 7 579 569 
1 51 8 122 110 
1 50 9 86 76 
1 52 10 76 66 
2 6 1 158 148 
2 5 2 194 184 
2 89 3 496 486 
2 32 4 578 568 
2 1 5 204 194 
2 3 6 321 311 
2 4 7 16 6 
2 2 8 303 293 
3 10 4 438 428 
3 57 5 373 363 
3 35 6 489 479 
3 12 7 755 745 
3 13 8 436 426 
3 11 9 182 . 172 
3 7 10 260 250 
3 49 11 145 135 
3 34 12 456 446 
3 36 13 280 270 
• 4 45 1 369 359 
4 47 2 438 428 
4 38 3 235 225 
4 42 4 336 326 
5 43 2 367 357 
5 46 3 302 292 
5 44 4 412 402 
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Solutions 
TRIS-BORA TE (TOE) 
TO MAKE 1 LITRE OF X10: 
11 Og Tris Base 
55g Bori� Acid 
40 ml 0.5M EDTA (pH8.0) 
Make up to 1 litre with distilled H20. 
(modified from Sambrook et
al., 1989, 8.23) 
DEIONISED FORMAMIDE 
Add 5 gnitre mixed bed resin beads and stir on a magnetic stirrer 
for 1 hour. 
Filter twice through Whatman No. 1 paper. 
Store small aliquots under nitrogen at -70°C. 
(Sambrook et al., 1989, p. 
1.102) 
FORMAMIDE LOADING BUFFER 
80% Forrnamide (deionised) 
10mM EDTA (pH 8.0) 
1 mg/ml Xylene Cyanol FF 
1 mg/ml Bromophenol Blue 
(Sambrook et al., 1989, p. 
7.76) 
TRIS (1M) 
TO MAKE 1 LITRE: 
Dissolve 121.1g of Tris base in 800ml of H20. 
Adjust the pH to the desired value by adding concentrated HCI. 
For pH 7.4 add approximately 70 ml HCI 
pH 7.6 " " 60 ml HCI 
pH 8.0 " " 42 ml HCI. 
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(San.brook et al., 1989, 
B. 13)
EDTA (0.5 M, pH 8.0) 
TO MAKE 1 LITRE: 
Add 186.1 g of disodium ethylenediaminetetraacetate.2H20 to 800 
mlofH20. 
Stir vigorously on a magnetic stirrer. Adjust the pH to 8.0 with 
NaOH (-20 g of NaOH pellets). Sterilize by autoclaving. 
(Sambrook et al., 1989, 
B. 11)
25% AMMONIUM PERSULPHATE 
TO MAKE 10 ML: 
To 2.5 g of ammonium persulphate, add H20 to 10 ml. Store at 
4'C. Make up fresh solution weekly. 
(modified from Sambrook et al., 1989, 
B. 10)
LIQUID ACRYLAMIDE (for radioactive labelling) 
TO MAKE 1 LITRE: 
Dissolve 420.5 g urea in H20 and make up to 700 mis. 
Add 150 ml "Liqui-mix-19" for a 6% gel or 100 ml "Liqui-mix-19" for 
a 4% gel. 
Deionise for 30 minutes by adding 5 g/litre mixed bed resin be;,ids 
and stirring on a magnetic stirrer. 
Filter once using Whatman No. 1 paper. Make up volume to 900 
ml. Add 100 ml of 10X TBE.
Degas (under vacuum) for 30 minutes. Wrap bottle in alfoil and 
store at 4'C. 
(modified from Sambrook et al.,
1989, p. 13.47) 
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5.12' AMPLIFICATION BUFFER
(This buffer is used in PCR reactions. 5 = SX buffer, 1 = 1mM 
magnesium chloride, 20 = 20 uM of each dNTP in the 
final reaction solution) 
TO MAKE 1 ML: 
10X Amplification buffer (Biotech) 
H20 
SmM dNTPmix 
1 M MgCl2
5.1.5250 AMPLIFICATION BUFFER 
500 UL 
475 UL 
20 uL 
5 UL 
(This buffer is used in PCR reactions. 5 = 5X buffer, 1.5 = 1.5 mM 
ma gnesium chloride, 250 = 250 uM of each dNTP in the 
final reaction solution) 
10X Amplification buffer (Biotech) 
H20 
SmMdNTPmix 
1 M MgCl2
GEL FIXATIVE 
10% Methanol 
10% Glacial Acetic Acid 
TO MAKE 2.5 LITRES: 
250 ml Methanol 
250 ml Glacial Acetic Acid 
2 Litres H20 
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500. _L
448.5 uL
50.0 uL 
1.5 uL 
APPENDIX E 
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LABORATORY METHODS 
PROTOCOLS 
Capillary system (PCR modification) 
The standard 0.65 ml reaction tubes were replaced by a �apillary system 
which used a programmable pipettor (Corbett Research). This system 
was optimised ir. the laboratory (by D.Chandler) in order to increase 
efficiency and reduce costs. This was achieved firstly by a reduction of 
reagents from 20 uUreaction to 5 uUreaction. Secondly, a reduction in 
thermal cycling time from an average of -7 minutes/cycle to -3 
minutes/cycle was achieved. Finally, a 36-well block replaced the 
standard 16-well block in the thermal cycler (MJ Research). These last 
two modifications greatly increased throughput. 
PCR with radioactive labelling 
Master mix X1 
These quantities are for one reaction volume of 5 ul. 
Add the following 5 reagents to a 0.65 ml microcentrifuge tube in order: 
H20 1.6 ul 
5.120 amplification buffer 1.0 ul (see 'Solutions" Appendix D) 
Primer (1.6 uM) 0.25 ul 
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Tth plus or Taq enzyme 0.05 uL (0.3 units/reaction) 
32P dCTP 
Target DNA 
0.1 uL (specific activity 3000CUmM) 
3.0 uL 
2.0 uL 
Master mix X60 
This is a 60 times mix used for 45-50 samples. 
60 ul5.1 20 Amplification Buffer 
15 ul Primer ( 1.6 uM) 
3 ul Tth Plus Enzyme ( 0.3 units/reaction) 
4 ul 32P (specific activity 3000 Ci/mM) 
180 ul total volume 
PCR Method: 
• 
• 
• 
• 
Pipette- 2 u/ of the target DNA into capillary (Corbett capillary 
pipettor) 
Pipette - 3 ul of master mix 
Cap capillary to prevent leakage 
Place into a thermocycler (MJ Research) programmed as follows: 
Step 1 
Step2 
Step 3 
Step4 
94° C for 5 minutes 
94 •c for 20 seconds 
55°C for 40 seconds 
72°C for 1 minute 
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Repeat steps 2 to 4, 29 times 
PostPCR: 
• 
• 
Expel amplified sample into labelled 0.65 ml microcentrifuge tube 
containing 8 ul of fonnamide loading buffer (see 'Solutions" 
Appendix D). 
While gel is warming pre-run: 
Place tube into a heating block for 5 minutEis denaturing at 94'C . 
Preparation of glass plates (used with Hoefer Poker Face sequencer for 
radioactively labelled products) 
* Wash two glass plates (37cm x 44cm and 37cm x 41cm) in hot 
water and liquid pyroneg (Diversey) detergent. 
• Rinse with hot water 
* Spray with 70% ethanol 
• Wipe dry with tissues 
* Silanise the smaller back plate with "Sigmacote' (Sigma 
Chemicals) 
• Allow to dry 
• Place the two plates together with 0.35mm nylon spacers 
between them at the lung edges. 
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• 
• 
• 
Place three bulldog clamps at each side leaving the bottom third 
of the plates free. 
Tape bottom one third with masking tape 
Place a small wedge centrally at the top between the two plates to 
assist with the pouring of the gel. 
Pouring a polyacrylamide gel (used with Hoefer Poker Face sequencer 
for radioactively labelled products) 
• 
• 
• 
• 
• 
• 
• 
• 
Pour 70 mls of liquid acrylamide 1 into a 250 ml beaker 
Add 170 ul tetramethylethylenediamine (Temed) 
Add 170 uL 25% ammonium persulphate 
Mix carefully and draw up without delay into a 50mL syringe 
Inject between the glass plates held at a slight incline 
Place the plates horizontally, remove the wedge 
Insert the well-forming spacer 
Leave to set at room temperature for at least one hour before 
use. 
'(19:1 acrylamide:bisacrylamide, Gradipore Liqui-Mix, see "Solutions' 
Appendix D) 
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Assembling the electrophoresis apparatus (Radioactive labelling) 
The SE1600 Poker Face II sequencer (Hoefer Scientific Instruments) was 
used with the 3000Xi electrophoresis power supply (Bio-Rad). 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Add enough 1X TBE buffer (see"Solutions' Appendix DJ to cover 
electrode in lower buffer chamber. 
Remove masking tape from the glass plates 
Place aluminium and perspex backing plate against the smaller 
glass plate (this functions to provide even heat distribution across 
the gel). 
Clamp backing plate into place with the two side clamps provided . 
Place this unit into a vertical position in the lower buffer tank and 
secure. 
Fill upper buffer tank with 1X TBE buffer 
Remove well-forming spacer and flush out well with 1X TBE (this 
removes excess urea). 
Place top safety lid and connectors and bottom connectors into 
position 
Plug power leads into the power supply . 
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Polyacrylamlde gel electrophoresis (used with Hoefer Poker Face 
sequencer for radioactively labelled products) 
• 
• 
• 
• 
• 
• 
Pre-warm gel for 20 minutes (connect to power supply and set the 
voltage at 1400V) 
Place tubes containing amplified products and formamide loading 
buffer into a heating block at 90°C for 5 minutes to denature the 
double-stranded DNA. 
Place tubes into ice to prevent evaporation and/or re-annealing of 
the complementary strands. 
Load 1 to 2 uL of each sample was loaded (1 uL for small weils of 
the 66-well comb, 2 uL for the 44-well comb). 
Replace top safety cover 
Run gel for 1 hour 30 minutes to 3 hours 30 minutes at 1400 
volts depending on the size range of the alleles and percentage 
acrylamide. 
4% >200bp 2.5 - 3 hours 
6% >200bp 3 -3.5 hours 
6% 150->200bp 2.5 - 3 hours 
8% <100bp 1.5 -2 hours 
Note: For tetranucleotide repeat markers less time will be needed 
compared to dinucleotide repeats for separation of alleles. 
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Post-run (procedures for radioactive labelllng) 
* 
* 
* 
* 
•  
* 
* 
• 
* 
• 
• 
Disconnect power supply 
Remove upper safety lid and connectors 
Empty upper buffer tank 
Remove side clamps 
Prize apart the two glass plates using a wedge and remove the 
plat e without the gel 
Fix gel with 10% methanol 10% glacial acetic acid for 15 minutes 
Drain excess moisture and place a piece of blotting paper 
slightly larger than the gel on top of the gel. 
Peel off paper with gel attached and cover gel side with plastic 
wrap. 
Place gel on a slab gel dryer (Savant SGD4050) at 80°C for 1 hour 
under vacuum. 
Place dry gel in an x-ray cassette (Amersham Hypercassette j 
with a sheet of x-ray film and leave at room temperature overnight. 
Develop x-ray film (Curix benchtop automatic processor, Agfa) . 
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Preparation of polyacrylamide (fluorescent labe11lng) 
* 
* 
* 
* 
* 
* 
* 
Place 15 gms urea (molecular biology grade) Into a 250 ml 
Erlenmeyer flask 
Add 4.5 mis of Liqui-gel (40%, 19:1 acrylamide:bis) 
Add 10.75 mis ofMilli-Q water 
Add 3 mis of 1 OX TBE (see "Solutions" Appendix D). 
Cover with parafilm and dissolve under warm running water 
Filter the solution through a 0.22mm pore size filter (Nalgene 
vacuum filter unit). 
De-gas under vacuum for 10 minutes. 
Pouring polyacrylamide gel (fluorescent labelling) 
* 
* 
* 
* 
* 
* 
* 
* 
Make up 250 ul of 10% ammonium persulphate (APS) (0.025 
gms in 250 ul Milli-Q water) 
Pour 20 mls of freshly prepared acrylamide into a 100 ml 
beaker 
Add 250 ul of APS 
Add 25 ul of TEMED 
Draw up solution without delay into a 50ml syrtnge 
Inject solution between the horizontally placed glass plates 
When the solution reaches the top of the plates remove the 
wedge 
Insert a well-forming spacer 
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• Leave gel to set at room temperature for at least one hour
before use.
PCR with fluorescent dUTP labe11lng 
• Dilute [f]dUTPs (separate tubes) as follows:
40uM for Tamra: Add 1ul of 400uM Tamra to 9ul of Tris buffer (pH 
9.5) 
10 uM for R6G : Add 1ul of 100uM to 9 ul Tris buffer (pH 9.5). 
1 O uM for R11 O : Add 1 ul of 100 uM to 9 ul Tris buffer (pH 9.5). 
Master mix: 
These quantities are for one reaction volume of 5 ul. 
Add the following 5 reagents to a 0.65 ml microcentrifuge tube in 
order: 
1.4 ul 
5.1.5250 amplification buffer 1.0 ul (refer "Solutions' 
Appendix D) 
Primer [0.5 uM] 
Tth plus or Taq enzyme 
[F]Dutp
Target DNA 
0.25 uL 
0.1 uL (0.3 units/reaction) 
0.25 uL 
3.0 ul 
2.0 uL 
PCRMethod: 
•
• 
Pipette - 2 ul of the target DNA into capillary (Corbett
capillary plpettor)
Pipette - 3 u/ of master mix
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•• 
Cap capillary to prevent leakage
Place into a thermocycler (MJ Research) programmed as
'follows:
Step 1 94 ° C for 5 minutes 
Step2 
Step 3 
Step4 
94°C for 20 seconds 
55°C for 40 seconds 
12°c for 1 minute 
Repeat steps 2 to 4, 29 times 
Post PCR: 
• 
• 
• 
• 
Expel amplified sample into labelled 0.65 mL microcentrtfuge 
tube containing 10 ul of water. 
Add 1 ul of each sample to be pooled (run in the same lane) 
to a new 0.65 mL tube with 5 ul loading buffer (1 part Dextran 
blue, 5 parts distilled and deionised molecular biology grade 
formamide). 
Add 0.5 ul sizing standard dye (ROX 500) to each tube . 
Place tubes into a heating block for 5 minutes denaturtng at 
94•c. 
The gels are run on an ABI Prism™ 373 DNA sequencer with 
GeneScan™ software (Perkin-Elmer). 
12S 
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MATERIALS 
List of chemicals 
Chemical 
Deoxynucleotide triphosphates (dNTPs) 
100mM (Concentration: 40 uMole) 
Tth Plus DNA Polymerase (5.5 units/ul) 
Magnesium Chloride (MgCI2) (1.00M) 
Glacial Acetic Acid (CH3COOH) 
Methanol (CH30H) 
Supplier 
Biotech International 
Ltd. 
Biotech International 
Ltd. 
Sigma Chemical Co. 
BDH 
BDH 
Liqui-gel (Liqui-mix-19: Acrylamide/Bis 19:1) Gradipore Ltd. 
Boric Acicl (H3B03) 
Tetramethylethylenediamine (TEMED) 
(C5H,.N2) 
Ammonium Persulphate (NH4hS20 8 
Analytical Grade Mixed Bed Resin 
Chlorinated organopolysiloxane in 
Heptane (Sigmacote) 
Formamide (CH3NO) 
Xylene Cyanole FF (C25H27N20 5S2Na) 
Bromephenol blue (Tetrabromophenolsulfo-
nephthalein)(C19H9Br405SNa) 
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Sigma Chemical Co. 
Sigma Chemical Co. 
Sigma Chemical Co. 
Bio-rad 
Sigma Chemical Co. 
Sigma Chemical Co. 
Sigma Chemical Co. 
Sigma Chemical Co. 
Tris[HydroxymethyQaminomethane (C4H11 NO,) 
(Trizma Base) 
Sodium Hydroxide (NaOH) 
Urea (CH4N20) 
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Sigma Chemical Co. 
Ajax Chemicals 
Sigma Chemical Co. 
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